<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">35767459</PMID><DateCompleted><Year>2022</Year><Month>12</Month><Day>15</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>08</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1941-7225</ISSN><JournalIssue CitedMedium="Internet"><Volume>35</Volume><Issue>12</Issue><PubDate><Year>2022</Year><Month>Dec</Month><Day>08</Day></PubDate></JournalIssue><Title>American journal of hypertension</Title><ISOAbbreviation>Am J Hypertens</ISOAbbreviation></Journal><ArticleTitle>Primary Aldosteronism: State-of-the-Art Review.</ArticleTitle><Pagination><StartPage>967</StartPage><EndPage>988</EndPage><MedlinePgn>967-988</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/ajh/hpac079</ELocationID><Abstract><AbstractText>We are witnessing a revolution in our understanding of primary aldosteronism (PA). In the past 2 decades, we have learned that PA is a highly prevalent syndrome that is largely attributable to pathogenic somatic mutations, that contributes to cardiovascular, metabolic, and kidney disease, and that when recognized, can be adequately treated with widely available mineralocorticoid receptor antagonists and/or surgical adrenalectomy. Unfortunately, PA is rarely diagnosed, or adequately treated, mainly because of a lack of awareness and education. Most clinicians still possess an outdated understanding of PA; from primary care physicians to hypertension specialists, there is an urgent need to redefine and reintroduce PA to clinicians with a modern and practical approach. In this state-of-the-art review, we provide readers with the most updated knowledge on the pathogenesis, prevalence, diagnosis, and treatment of PA. In particular, we underscore the public health importance of promptly recognizing and treating PA and provide pragmatic solutions to modify clinical practices to achieve this.</AbstractText><CopyrightInformation>&#xa9; The Author(s) 2022. Published by Oxford University Press on behalf of American Journal of Hypertension, Ltd. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Vaidya</LastName><ForeName>Anand</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-0314-9252</Identifier><AffiliationInfo><Affiliation>Department of Medicine, Center for Adrenal Disorders, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hundemer</LastName><ForeName>Gregory L</ForeName><Initials>GL</Initials><AffiliationInfo><Affiliation>Department of Medicine (Division of Nephrology) and the Ottawa Hospital Research Institute, University of Ottawa, Ottawa, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nanba</LastName><ForeName>Kazutaka</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Endocrinology and Metabolism, National Hospital Organization Kyoto Medical Center, Kyoto, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Molecular and Integrative Physiology, University of Michigan, Ann Arbor, Michigan, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Parksook</LastName><ForeName>Wasita W</ForeName><Initials>WW</Initials><AffiliationInfo><Affiliation>Department of Medicine, Division of Endocrinology and Metabolism, and Division of General Internal Medicine, Faculty of Medicine, Chulalongkorn University, and King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok, Thailand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brown</LastName><ForeName>Jenifer M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 HL155834</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K23HL159279</GrantID><Acronym>HB</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K23 HL159279</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 DK115392</GrantID><Acronym>NH</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 HL153004</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K01 DA016618</GrantID><Acronym>DA</Acronym><Agency>NIDA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 HL155834</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002541</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K23 HL159279</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Hypertens</MedlineTA><NlmUniqueID>8803676</NlmUniqueID><ISSNLinking>0895-7061</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">adrenal</Keyword><Keyword MajorTopicYN="N">aldosterone</Keyword><Keyword MajorTopicYN="N">blood pressure</Keyword><Keyword MajorTopicYN="N">hypertension</Keyword><Keyword MajorTopicYN="N">primary aldosteronism</Keyword><Keyword MajorTopicYN="N">renin</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>5</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>6</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>6</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>6</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>6</Month><Day>30</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>6</Month><Day>29</Day><Hour>13</Hour><Minute>2</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>6</Month><Day>29</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35767459</ArticleId><ArticleId IdType="pmc">PMC9729786</ArticleId><ArticleId IdType="doi">10.1093/ajh/hpac079</ArticleId><ArticleId IdType="pii">6620780</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Scholl UI. Genetics of primary aldosteronism. Hypertension 2022; 79:887&#x2013;897.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8997684</ArticleId><ArticleId IdType="pubmed">35139664</ArticleId></ArticleIdList></Reference><Reference><Citation>Zennaro MC, Boulkroun S, Fernandes-Rosa F. Genetic causes of functional adrenocortical adenomas. Endocr Rev 2017; 38:516&#x2013;537.</Citation><ArticleIdList><ArticleId IdType="pubmed">28973103</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishimoto K, Nakagawa K, Li D, Kosaka T, Oya M, Mikami S, Shibata H, Itoh H, Mitani F, Yamazaki T, Ogishima T, Suematsu M, Mukai K. Adrenocortical zonation in humans under normal and pathological conditions. J Clin Endocrinol Metab 2010; 95:2296&#x2013;2305.</Citation><ArticleIdList><ArticleId IdType="pubmed">20200334</ArticleId></ArticleIdList></Reference><Reference><Citation>Gomez-Sanchez CE, Qi X, Velarde-Miranda C, Plonczynski MW, Parker CR, Rainey W, Satoh F, Maekawa T, Nakamura Y, Sasano H, Gomez-Sanchez EP. Development of monoclonal antibodies against human CYP11B1 and CYP11B2. Mol Cell Endocrinol 2014; 383:111&#x2013;117.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3939805</ArticleId><ArticleId IdType="pubmed">24325867</ArticleId></ArticleIdList></Reference><Reference><Citation>Nanba K, Tsuiki M, Sawai K, Mukai K, Nishimoto K, Usui T, Tagami T, Okuno H, Yamamoto T, Shimatsu A, Katabami T, Okumura A, Kawa G, Tanabe A, Naruse M. Histopathological diagnosis of primary aldosteronism using CYP11B2 immunohistochemistry. J Clin Endocrinol Metab 2013; 98:1567&#x2013;1574.</Citation><ArticleIdList><ArticleId IdType="pubmed">23443813</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyer LS, Wang X, Susnik E, Burrello J, Burrello A, Castellano I, Eisenhofer G, Fallo F, Kline GA, Knosel T, Kocjan T, Lenders JWM, Mulatero P, Naruse M, Nishikawa T, Peitzsch M, Rump LC, Beuschlein F, Hahner S, Gomez-Sanchez CE, Reincke M, Williams TA. Immunohistopathology and steroid profiles associated with biochemical outcomes after adrenalectomy for unilateral primary aldosteronism. Hypertension 2018; 72:650&#x2013;657.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6202235</ArticleId><ArticleId IdType="pubmed">30012870</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams TA, Gomez-Sanchez CE, Rainey WE, Giordano TJ, Lam AK, Marker A, Mete O, Yamazaki Y, Zerbini MCN, Beuschlein F, Satoh F, Burrello J, Schneider H, Lenders JWM, Mulatero P, Castellano I, Knosel T, Papotti M, Saeger W, Sasano H, Reincke M. International histopathology consensus for unilateral primary aldosteronism. J Clin Endocrinol Metab 2021; 106:42&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7765663</ArticleId><ArticleId IdType="pubmed">32717746</ArticleId></ArticleIdList></Reference><Reference><Citation>Mete O, Erickson LA, Juhlin CC, de Krijger RR, Sasano H, Volante M, Papotti MG. Overview of the 2022 WHO classification of adrenal cortical tumors. Endocr Pathol 2022; 33:155&#x2013;196.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8920443</ArticleId><ArticleId IdType="pubmed">35288842</ArticleId></ArticleIdList></Reference><Reference><Citation>Nanba AT, Nanba K, Byrd JB, Shields JJ, Giordano TJ, Miller BS, Rainey WE, Auchus RJ, Turcu AF. Discordance between imaging and immunohistochemistry in unilateral primary aldosteronism. Clin Endocrinol 2017; 87:665&#x2013;672.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5698145</ArticleId><ArticleId IdType="pubmed">28787766</ArticleId></ArticleIdList></Reference><Reference><Citation>Omata K, Yamazaki Y, Nakamura Y, Anand SK, Barletta JA, Sasano H, Rainey WE, Tomlins SA, Vaidya A. Genetic and histopathologic intertumor heterogeneity in primary aldosteronism. J Clin Endocrinol Metab 2017; 102:1792&#x2013;1796.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5470766</ArticleId><ArticleId IdType="pubmed">28368480</ArticleId></ArticleIdList></Reference><Reference><Citation>Fallo F, Castellano I, Gomez-Sanchez CE, Rhayem Y, Pilon C, Vicennati V, Santini D, Maffeis V, Fassina A, Mulatero P, Beuschlein F, Reincke M. Histopathological and genetic characterization of aldosterone-producing adenomas with concurrent subclinical cortisol hypersecretion: a case series. Endocrine 2017; 58:503&#x2013;512.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5638684</ArticleId><ArticleId IdType="pubmed">28405879</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang L, Li X, Wang B, Ma X, Li H, Gao Y, Gu L, Nie W, Zhang X. Clinical characteristics of aldosterone- and cortisol-coproducing adrenal adenoma in primary aldosteronism. Int J Endocrinol 2018; 2018:4920841.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5889857</ArticleId><ArticleId IdType="pubmed">29770148</ArticleId></ArticleIdList></Reference><Reference><Citation>Teragawa H, Oshita C, Orita Y, Hashimoto K, Nakayama H, Yamazaki Y, Sasano H. Primary aldosteronism due to bilateral micronodular hyperplasia and concomitant subclinical Cushing&#x2019;s syndrome: a case report. World J Clin Cases 2021; 9:1119&#x2013;1126.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7896658</ArticleId><ArticleId IdType="pubmed">33644175</ArticleId></ArticleIdList></Reference><Reference><Citation>Fushimi Y, Tatsumi F, Sanada J, Shimoda M, Kamei S, Nakanishi S, Kaku K, Mune T, Kaneto H. Concurrence of overt Cushing&#x2019;s syndrome and primary aldosteronism accompanied by aldosterone-producing cell cluster in adjacent adrenal cortex: case report. BMC Endocr Disord 2021; 21:163.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8359021</ArticleId><ArticleId IdType="pubmed">34384396</ArticleId></ArticleIdList></Reference><Reference><Citation>Nanba K, Omata K, Tomlins SA, Giordano TJ, Hammer GD, Rainey WE, Else T. Double adrenocortical adenomas harboring independent KCNJ5 and PRKACA somatic mutations. Eur J Endocrinol 2016; 175:K1&#x2013;K6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5030510</ArticleId><ArticleId IdType="pubmed">27165862</ArticleId></ArticleIdList></Reference><Reference><Citation>Stenman A, Shabo I, Ramstrom A, Zedenius J, Juhlin CC. Synchronous aldosterone- and cortisol-producing adrenocortical adenomas diagnosed using CYP11B immunohistochemistry. SAGE Open Med Case Rep 2019; 7. doi:10.1177/2050313X19883770</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/2050313X19883770</ArticleId><ArticleId IdType="pmc">PMC6801880</ArticleId><ArticleId IdType="pubmed">31666955</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Tan J, Yang Q, Du Z, Yang S, He W, Song Y, Hu J, Yang Y, Li Q, Zhang Y, He Y, Cheng Q; Chongqing Primary Aldosteronism Study (CONPASS) Group. Primary aldosteronism concurrent with subclinical Cushing&#x2019;s syndrome: a case report and review of the literature. J Med Case Rep 2020; 14:32.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7031945</ArticleId><ArticleId IdType="pubmed">32075693</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen YJ, Peng KY, Chueh JS, Liao HW, Hsieh TY, Wu VC, Wang SM. Case report: primary aldosteronism due to bilateral aldosterone-producing micronodules with HISTALDO classical and contralateral non-classical pathology. Front Endocrinol 2022; 13:816754.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8989467</ArticleId><ArticleId IdType="pubmed">35399924</ArticleId></ArticleIdList></Reference><Reference><Citation>Ren K, Wei J, Liu Q, Zhu Y, Wu N, Tang Y, Li Q, Zhang Q, Yu Y, An Z, Chen J, Li J. Hypercortisolism and primary aldosteronism caused by bilateral adrenocortical adenomas: a case report. BMC Endocr Disord 2019; 19:63.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6580498</ArticleId><ArticleId IdType="pubmed">31208392</ArticleId></ArticleIdList></Reference><Reference><Citation>Omata K, Satoh F, Morimoto R, Ito S, Yamazaki Y, Nakamura Y, Anand SK, Guo Z, Stowasser M, Sasano H, Tomlins SA, Rainey WE. Cellular and genetic causes of idiopathic hyperaldosteronism. Hypertension 2018; 72:874&#x2013;880.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6207209</ArticleId><ArticleId IdType="pubmed">30354720</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi M, Scholl UI, Yue P, Bjorklund P, Zhao B, Nelson-Williams C, Ji W, Cho Y, Patel A, Men CJ, Lolis E, Wisgerhof MV, Geller DS, Mane S, Hellman P, Westin G, Akerstrom G, Wang W, Carling T, Lifton RP. K+ channel mutations in adrenal aldosterone-producing adenomas and hereditary hypertension. Science 2011; 331:768&#x2013;772.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3371087</ArticleId><ArticleId IdType="pubmed">21311022</ArticleId></ArticleIdList></Reference><Reference><Citation>Scholl UI, Goh G, Stolting G, de Oliveira RC, Choi M, Overton JD, Fonseca AL, Korah R, Starker LF, Kunstman JW, Prasad ML, Hartung EA, Mauras N, Benson MR, Brady T, Shapiro JR, Loring E, Nelson-Williams C, Libutti SK, Mane S, Hellman P, Westin G, Akerstrom G, Bjorklund P, Carling T, Fahlke C, Hidalgo P, Lifton RP. Somatic and germline CACNA1D calcium channel mutations in aldosterone-producing adenomas and primary aldosteronism. Nat Genet 2013; 45:1050&#x2013;1054.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3876926</ArticleId><ArticleId IdType="pubmed">23913001</ArticleId></ArticleIdList></Reference><Reference><Citation>Nanba K, Blinder AR, Rege J, Hattangady NG, Else T, Liu CJ, Tomlins SA, Vats P, Kumar-Sinha C, Giordano TJ, Rainey WE. Somatic CACNA1H mutation as a cause of aldosterone-producing adenoma. Hypertension 2020; 75:645&#x2013;649.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7059016</ArticleId><ArticleId IdType="pubmed">31983310</ArticleId></ArticleIdList></Reference><Reference><Citation>Scholl UI, Stolting G, Nelson-Williams C, Vichot AA, Choi M, Loring E, Prasad ML, Goh G, Carling T, Juhlin CC, Quack I, Rump LC, Thiel A, Lande M, Frazier BG, Rasoulpour M, Bowlin DL, Sethna CB, Trachtman H, Fahlke C, Lifton RP. Recurrent gain of function mutation in calcium channel CACNA1H causes early-onset hypertension with primary aldosteronism. Elife 2015; 4:e06315.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4408447</ArticleId><ArticleId IdType="pubmed">25907736</ArticleId></ArticleIdList></Reference><Reference><Citation>Scholl UI, Stolting G, Schewe J, Thiel A, Tan H, Nelson-Williams C, Vichot AA, Jin SC, Loring E, Untiet V, Yoo T, Choi J, Xu S, Wu A, Kirchner M, Mertins P, Rump LC, Onder AM, Gamble C, McKenney D, Lash RW, Jones DP, Chune G, Gagliardi P, Choi M, Gordon R, Stowasser M, Fahlke C, Lifton RP. CLCN2 chloride channel mutations in familial hyperaldosteronism type II. Nat Genet 2018; 50:349&#x2013;354.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5862758</ArticleId><ArticleId IdType="pubmed">29403011</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernandes-Rosa FL, Daniil G, Orozco IJ, Goppner C, El Zein R, Jain V, Boulkroun S, Jeunemaitre X, Amar L, Lefebvre H, Schwarzmayr T, Strom TM, Jentsch TJ, Zennaro MC. A gain-of-function mutation in the CLCN2 chloride channel gene causes primary aldosteronism. Nat Genet 2018; 50:355&#x2013;361.</Citation><ArticleIdList><ArticleId IdType="pubmed">29403012</ArticleId></ArticleIdList></Reference><Reference><Citation>Beuschlein F, Boulkroun S, Osswald A, Wieland T, Nielsen HN, Lichtenauer UD, Penton D, Schack VR, Amar L, Fischer E, Walther A, Tauber P, Schwarzmayr T, Diener S, Graf E, Allolio B, Samson-Couterie B, Benecke A, Quinkler M, Fallo F, Plouin PF, Mantero F, Meitinger T, Mulatero P, Jeunemaitre X, Warth R, Vilsen B, Zennaro MC, Strom TM, Reincke M. Somatic mutations in ATP1A1 and ATP2B3 lead to aldosterone-producing adenomas and secondary hypertension. Nat Genet 2013; 45:440&#x2013;444, 444e1&#x2013;2.</Citation><ArticleIdList><ArticleId IdType="pubmed">23416519</ArticleId></ArticleIdList></Reference><Reference><Citation>Akerstrom T, Maharjan R, Sven Willenberg H, Cupisti K, Ip J, Moser A, Stalberg P, Robinson B, Alexander Iwen K, Dralle H, Walz MK, Lehnert H, Sidhu S, Gomez-Sanchez C, Hellman P, Bjorklund P. Activating mutations in CTNNB1 in aldosterone producing adenomas. Sci Rep 2016; 6:19546.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4728393</ArticleId><ArticleId IdType="pubmed">26815163</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu VC, Wang SM, Chueh SJ, Yang SY, Huang KH, Lin YH, Wang JJ, Connolly R, Hu YH, Gomez-Sanchez CE, Peng KY, Wu KD. The prevalence of CTNNB1 mutations in primary aldosteronism and consequences for clinical outcomes. Sci Rep 2017; 7:39121.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5244399</ArticleId><ArticleId IdType="pubmed">28102204</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou J, Azizan EAB, Cabrera CP, Fernandes-Rosa FL, Boulkroun S, Argentesi G, Cottrell E, Amar L, Wu X, O&#x2019;Toole S, Goodchild E, Marker A, Senanayake R, Garg S, Akerstrom T, Backman S, Jordan S, Polubothu S, Berney DM, Gluck A, Lines KE, Thakker RV, Tuthill A, Joyce C, Kaski JP, Karet Frankl FE, Metherell LA, Teo AED, Gurnell M, Parvanta L, Drake WM, Wozniak E, Klinzing D, Kuan JL, Tiang Z, Gomez Sanchez CE, Hellman P, Foo RSY, Mein CA, Kinsler VA, Bjorklund P, Storr HL, Zennaro MC, Brown MJ. Somatic mutations of GNA11 and GNAQ in CTNNB1-mutant aldosterone-producing adenomas presenting in puberty, pregnancy or menopause. Nat Genet 2021; 53:1360&#x2013;1372.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9082578</ArticleId><ArticleId IdType="pubmed">34385710</ArticleId></ArticleIdList></Reference><Reference><Citation>Nanba K, Omata K, Gomez-Sanchez CE, Stratakis CA, Demidowich AP, Suzuki M, Thompson LDR, Cohen DL, Luther JM, Gellert L, Vaidya A, Barletta JA, Else T, Giordano TJ, Tomlins SA, Rainey WE. Genetic characteristics of aldosterone-producing adenomas in blacks. Hypertension 2019; 73:885&#x2013;892.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6416065</ArticleId><ArticleId IdType="pubmed">30739536</ArticleId></ArticleIdList></Reference><Reference><Citation>Lifton RP, Dluhy RG, Powers M, Rich GM, Cook S, Ulick S, Lalouel JM. A chimaeric 11 beta-hydroxylase/aldosterone synthase gene causes glucocorticoid-remediable aldosteronism and human hypertension. Nature 1992; 355:262&#x2013;265.</Citation><ArticleIdList><ArticleId IdType="pubmed">1731223</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamada M, Nakajima Y, Taguchi R, Okamura T, Ishii S, Tomaru T, Ozawa A, Shibusawa N, Yoshino S, Toki A, Ishida E, Hashimoto K, Satoh T, Mori M. KCNJ5 mutations in aldosterone- and cortisol-co-secreting adrenal adenomas. Endocr J 2012; 59:735&#x2013;741.</Citation><ArticleIdList><ArticleId IdType="pubmed">22863749</ArticleId></ArticleIdList></Reference><Reference><Citation>Lerario AM, Nanba K, Blinder AR, Suematsu S, Omura M, Nishikawa T, Giordano TJ, Rainey WE, Else T. Genetics of aldosterone-producing adenomas with pathogenic KCNJ5 variants. Endocr Relat Cancer 2019; 26:463&#x2013;470.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7869655</ArticleId><ArticleId IdType="pubmed">30753137</ArticleId></ArticleIdList></Reference><Reference><Citation>Monticone S, Castellano I, Versace K, Lucatello B, Veglio F, Gomez-Sanchez CE, Williams TA, Mulatero P. Immunohistochemical, genetic and clinical characterization of sporadic aldosterone-producing adenomas. Mol Cell Endocrinol 2015; 411:146&#x2013;154.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4474471</ArticleId><ArticleId IdType="pubmed">25958045</ArticleId></ArticleIdList></Reference><Reference><Citation>Inoue K, Yamazaki Y, Kitamoto T, Hirose R, Saito J, Omura M, Sasano H, Nishikawa T. Aldosterone suppression by dexamethasone in patients with KCNJ5-mutated aldosterone-producing adenoma. J Clin Endocrinol Metab 2018; 103:3477&#x2013;3485.</Citation><ArticleIdList><ArticleId IdType="pubmed">30020487</ArticleId></ArticleIdList></Reference><Reference><Citation>De Sousa K, Boulkroun S, Baron S, Nanba K, Wack M, Rainey WE, Rocha A, Giscos-Douriez I, Meatchi T, Amar L, Travers S, Fernandes-Rosa FL, Zennaro MC. Genetic, cellular, and molecular heterogeneity in adrenals with aldosterone-producing adenoma. Hypertension 2020; 75:1034&#x2013;1044.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7098445</ArticleId><ArticleId IdType="pubmed">32114847</ArticleId></ArticleIdList></Reference><Reference><Citation>Oki K, Plonczynski MW, Luis Lam M, Gomez-Sanchez EP, Gomez-Sanchez CE. Potassium channel mutant KCNJ5 T158A expression in HAC-15 cells increases aldosterone synthesis. Endocrinology 2012; 153:1774&#x2013;1782.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3320257</ArticleId><ArticleId IdType="pubmed">22315453</ArticleId></ArticleIdList></Reference><Reference><Citation>Hattangady NG, Karashima S, Yuan L, Ponce-Balbuena D, Jalife J, Gomez-Sanchez CE, Auchus RJ, Rainey WE, Else T. Mutated KCNJ5 activates the acute and chronic regulatory steps in aldosterone production. J Mol Endocrinol 2016; 57:1&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5027885</ArticleId><ArticleId IdType="pubmed">27099398</ArticleId></ArticleIdList></Reference><Reference><Citation>Rhayem Y, Perez-Rivas LG, Dietz A, Bathon K, Gebhard C, Riester A, Mauracher B, Gomez-Sanchez C, Eisenhofer G, Schwarzmayr T, Calebiro D, Strom TM, Reincke M, Beuschlein F. PRKACA somatic mutations are rare findings in aldosterone-producing adenomas. J Clin Endocrinol Metab 2016; 101:3010&#x2013;3017.</Citation><ArticleIdList><ArticleId IdType="pubmed">27270477</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakajima Y, Okamura T, Horiguchi K, Gohko T, Miyamoto T, Satoh T, Ozawa A, Ishii S, Yamada E, Hashimoto K, Okada S, Takata D, Horiguchi J, Yamada M. GNAS mutations in adrenal aldosterone-producing adenomas. Endocr J 2016; 63:199&#x2013;204.</Citation><ArticleIdList><ArticleId IdType="pubmed">26743443</ArticleId></ArticleIdList></Reference><Reference><Citation>Nanba K, Omata K, Else T, Beck PCC, Nanba AT, Turcu AF, Miller BS, Giordano TJ, Tomlins SA, Rainey WE. Targeted molecular characterization of aldosterone-producing adenomas in white Americans. J Clin Endocrinol Metab 2018; 103:3869&#x2013;3876.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6179168</ArticleId><ArticleId IdType="pubmed">30085035</ArticleId></ArticleIdList></Reference><Reference><Citation>Nanba K, Rainey WE. Genetics in Endocrinology: impact of race and sex on genetic causes of aldosterone-producing adenomas. Eur J Endocrinol 2021; 185:R1&#x2013;R11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8480207</ArticleId><ArticleId IdType="pubmed">33900205</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishimoto K, Tomlins SA, Kuick R, Cani AK, Giordano TJ, Hovelson DH, Liu CJ, Sanjanwala AR, Edwards MA, Gomez-Sanchez CE, Nanba K, Rainey WE. Aldosterone-stimulating somatic gene mutations are common in normal adrenal glands. Proc Natl Acad Sci USA 2015; 112:E4591&#x2013;E4599.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4547250</ArticleId><ArticleId IdType="pubmed">26240369</ArticleId></ArticleIdList></Reference><Reference><Citation>Omata K, Anand SK, Hovelson DH, Liu CJ, Yamazaki Y, Nakamura Y, Ito S, Satoh F, Sasano H, Rainey WE, Tomlins SA. Aldosterone-producing cell clusters frequently harbor somatic mutations and accumulate with age in normal adrenals. J Endocr Soc 2017; 1:787&#x2013;799.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5686701</ArticleId><ArticleId IdType="pubmed">29264530</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishimoto K, Seki T, Hayashi Y, Mikami S, Al-Eyd G, Nakagawa K, Morita S, Kosaka T, Oya M, Mitani F, Suematsu M, Kabe Y, Mukai K. Human adrenocortical remodeling leading to aldosterone-producing cell cluster generation. Int J Endocrinol 2016; 2016:7834356.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5046023</ArticleId><ArticleId IdType="pubmed">27721827</ArticleId></ArticleIdList></Reference><Reference><Citation>Nanba K, Vaidya A, Williams GH, Zheng I, Else T, Rainey WE. Age-related autonomous aldosteronism. Circulation 2017; 136:347&#x2013;355.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5568806</ArticleId><ArticleId IdType="pubmed">28566337</ArticleId></ArticleIdList></Reference><Reference><Citation>Nanba K, Vaidya A, Rainey WE. Aging and adrenal aldosterone production. Hypertension 2018; 71:218&#x2013;223.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5839673</ArticleId><ArticleId IdType="pubmed">29229745</ArticleId></ArticleIdList></Reference><Reference><Citation>Sugiura Y, Takeo E, Shimma S, Yokota M, Higashi T, Seki T, Mizuno Y, Oya M, Kosaka T, Omura M, Nishikawa T, Suematsu M, Nishimoto K. Aldosterone and 18-oxocortisol coaccumulation in aldosterone-producing lesions. Hypertension 2018; 72:1345&#x2013;1354.</Citation><ArticleIdList><ArticleId IdType="pubmed">30571232</ArticleId></ArticleIdList></Reference><Reference><Citation>Takeo E, Sugiura Y, Uemura T, Nishimoto K, Yasuda M, Sugiyama E, Ohtsuki S, Higashi T, Nishikawa T, Suematsu M, Fukusaki E, Shimma S. Tandem mass spectrometry imaging reveals distinct accumulation patterns of steroid structural isomers in human adrenal glands. Anal Chem 2019; 91:8918&#x2013;8925.</Citation><ArticleIdList><ArticleId IdType="pubmed">31204806</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown JM, Siddiqui M, Calhoun DA, Carey RM, Hopkins PN, Williams GH, Vaidya A. The unrecognized prevalence of primary aldosteronism: a cross-sectional study. Ann Intern Med 2020; 173:10&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7459427</ArticleId><ArticleId IdType="pubmed">32449886</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishimoto K, Seki T, Kurihara I, Yokota K, Omura M, Nishikawa T, Shibata H, Kosaka T, Oya M, Suematsu M, Mukai K. Case report: nodule development from subcapsular aldosterone-producing cell clusters causes hyperaldosteronism. J Clin Endocrinol Metab 2016; 101:6&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">26580238</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishimoto K, Koga M, Seki T, Oki K, Gomez-Sanchez EP, Gomez-Sanchez CE, Naruse M, Sakaguchi T, Morita S, Kosaka T, Oya M, Ogishima T, Yasuda M, Suematsu M, Kabe Y, Omura M, Nishikawa T, Mukai K. Immunohistochemistry of aldosterone synthase leads the way to the pathogenesis of primary aldosteronism. Mol Cell Endocrinol 2017; 441:124&#x2013;133.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5470036</ArticleId><ArticleId IdType="pubmed">27751767</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun N, Meyer LS, Feuchtinger A, Kunzke T, Knosel T, Reincke M, Walch A, Williams TA. Mass spectrometry imaging establishes 2 distinct metabolic phenotypes of aldosterone-producing cell clusters in primary aldosteronism. Hypertension 2020; 75:634&#x2013;644.</Citation><ArticleIdList><ArticleId IdType="pubmed">31957522</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernandes-Rosa FL, Boulkroun S, Zennaro MC. Genetic and genomic mechanisms of primary aldosteronism. Trends Mol Med 2020; 26:819&#x2013;832.</Citation><ArticleIdList><ArticleId IdType="pubmed">32563556</ArticleId></ArticleIdList></Reference><Reference><Citation>Vouillarmet J, Fernandes-Rosa F, Graeppi-Dulac J, Lantelme P, Decaussin-Petrucci M, Thivolet C, Peix JL, Boulkroun S, Clauser E, Zennaro MC. Aldosterone-producing adenoma with a somatic KCNJ5 mutation revealing APC-dependent familial adenomatous polyposis. J Clin Endocrinol Metab 2016; 101:3874&#x2013;3878.</Citation><ArticleIdList><ArticleId IdType="pubmed">27648962</ArticleId></ArticleIdList></Reference><Reference><Citation>St-Jean M, Bourdeau I, Martin M, Lacroix A. Aldosterone is aberrantly regulated by various stimuli in a high proportion of patients with primary aldosteronism. J Clin Endocrinol Metab 2021; 106:e45&#x2013;e60.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7765652</ArticleId><ArticleId IdType="pubmed">33000146</ArticleId></ArticleIdList></Reference><Reference><Citation>St-Jean M, Ghorayeb NE, Bourdeau I, Lacroix A. Aberrant G-protein coupled hormone receptor in adrenal diseases. Best Pract Res Clin Endocrinol Metab 2018; 32:165&#x2013;187.</Citation><ArticleIdList><ArticleId IdType="pubmed">29678284</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez AG, Duparc C, Naccache A, Castanet M, Lefebvre H, Louiset E. Role of mast cells in the control of aldosterone secretion. Horm Metab Res 2020; 52:412&#x2013;420.</Citation><ArticleIdList><ArticleId IdType="pubmed">32215882</ArticleId></ArticleIdList></Reference><Reference><Citation>De Sousa K, Abdellatif AB, Giscos-Douriez I, Meatchi T, Amar L, Fernandes-Rosa FL, Boulkroun S, Zennaro MC. Colocalization of Wnt/beta-catenin and ACTH signaling pathways and paracrine regulation in aldosterone producing adenoma. J Clin Endocrinol Metab 2021; 107:419&#x2013;434. doi:10.1210/clinem/dgab707</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/clinem/dgab707</ArticleId><ArticleId IdType="pubmed">34570225</ArticleId></ArticleIdList></Reference><Reference><Citation>Huby AC, Antonova G, Groenendyk J, Gomez-Sanchez CE, Bollag WB, Filosa JA, Belin de Chantemele EJ. Adipocyte-derived hormone leptin is a direct regulator of aldosterone secretion, which promotes endothelial dysfunction and cardiac fibrosis. Circulation 2015; 132:2134&#x2013;2145.</Citation><ArticleIdList><ArticleId IdType="pubmed">26362633</ArticleId></ArticleIdList></Reference><Reference><Citation>El Ghorayeb N, Bourdeau I, Lacroix A. Role of ACTH and other hormones in the regulation of aldosterone production in primary aldosteronism. Front Endocrinol 2016; 7:72.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4921457</ArticleId><ArticleId IdType="pubmed">27445975</ArticleId></ArticleIdList></Reference><Reference><Citation>Gouli A, Kaltsas G, Tzonou A, Markou A, Androulakis II, Ragkou D, Vamvakidis K, Zografos G, Kontogeorgos G, Chrousos GP, Piaditis G. High prevalence of autonomous aldosterone secretion among patients with essential hypertension. Eur J Clin Invest 2011; 41:1227&#x2013;1236.</Citation><ArticleIdList><ArticleId IdType="pubmed">21534948</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim JS, Plaska SW, Rege J, Rainey WE, Turcu AF. Aldosterone-regulating receptors and aldosterone-driver somatic mutations. Front Endocrinol 2021; 12:644382.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8008747</ArticleId><ArticleId IdType="pubmed">33796077</ArticleId></ArticleIdList></Reference><Reference><Citation>Markou A, Sertedaki A, Kaltsas G, Androulakis II, Marakaki C, Pappa T, Gouli A, Papanastasiou L, Fountoulakis S, Zacharoulis A, Karavidas A, Ragkou D, Charmandari E, Chrousos GP, Piaditis GP. Stress-induced aldosterone hyper-secretion in a substantial subset of patients with essential hypertension. J Clin Endocrinol Metab 2015; 100:2857&#x2013;2864.</Citation><ArticleIdList><ArticleId IdType="pubmed">25974737</ArticleId></ArticleIdList></Reference><Reference><Citation>Funder JW. The potential of ACTH in the genesis of primary aldosteronism. Front Endocrinol 2016; 7:40.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4876424</ArticleId><ArticleId IdType="pubmed">27242664</ArticleId></ArticleIdList></Reference><Reference><Citation>Gagnon N, Caceres-Gorriti KY, Corbeil G, El Ghoyareb N, Ludwig N, Latour M, Lacroix A, Bourdeau I. Genetic characterization of GnRH/LH-responsive primary aldosteronism. J Clin Endocrinol Metab 2018; 103:2926&#x2013;2935.</Citation><ArticleIdList><ArticleId IdType="pubmed">29726953</ArticleId></ArticleIdList></Reference><Reference><Citation>De Sousa K, Abdellatif AB, Giscos-Douriez I, Meatchi T, Amar L, Fernandes-Rosa FL, Boulkroun S, Zennaro MC. Colocalization of Wnt/beta-catenin and ACTH signaling pathways and paracrine regulation in aldosterone-producing adenoma. J Clin Endocrinol Metab 2022; 107:419&#x2013;434.</Citation><ArticleIdList><ArticleId IdType="pubmed">34570225</ArticleId></ArticleIdList></Reference><Reference><Citation>Lampron A, Bourdeau I, Oble S, Godbout A, Schurch W, Arjane P, Hamet P, Lacroix A. Regulation of aldosterone secretion by several aberrant receptors including for glucose-dependent insulinotropic peptide in a patient with an aldosteronoma. J Clin Endocrinol Metab 2009; 94:750&#x2013;756.</Citation><ArticleIdList><ArticleId IdType="pubmed">19066304</ArticleId></ArticleIdList></Reference><Reference><Citation>Zwermann O, Suttmann Y, Bidlingmaier M, Beuschlein F, Reincke M. Screening for membrane hormone receptor expression in primary aldosteronism. Eur J Endocrinol 2009; 160:443&#x2013;451.</Citation><ArticleIdList><ArticleId IdType="pubmed">19131502</ArticleId></ArticleIdList></Reference><Reference><Citation>Sinclair AM, Isles CG, Brown I, Cameron H, Murray GD, Robertson JWK.. Secondary hypertension in a blood pressure clinic. Arch Intern Med 1987; 147:1289&#x2013;1289.</Citation><ArticleIdList><ArticleId IdType="pubmed">3606286</ArticleId></ArticleIdList></Reference><Reference><Citation>Vasan RS, Evans JC, Larson MG, Wilson PWF, Meigs JB, Rifai N, Benjamin EJ, Levy D. Serum aldosterone and the incidence of hypertension in nonhypertensive persons. N Engl J Med 2004; 351:33&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">15229305</ArticleId></ArticleIdList></Reference><Reference><Citation>Newton-Cheh C, Guo C-YY, Gona P, Larson MG, Benjamin EJ, Wang TJ, Kathiresan S, O&#x2019;Donnell CJ, Musone SL, Camargo AL, Drake JA, Levy D, Hirschhorn JN, Vasan RS. Clinical and genetic correlates of aldosterone-to-renin ratio and relations to blood pressure in a community sample. Hypertension 2007; 49:846&#x2013;856.</Citation><ArticleIdList><ArticleId IdType="pubmed">17296870</ArticleId></ArticleIdList></Reference><Reference><Citation>Markou A, Pappa T, Kaltsas G, Gouli A, Mitsakis K, Tsounas P, Prevoli A, Tsiavos V, Papanastasiou L, Zografos G, Chrousos GP, Piaditis GP. Evidence of primary aldosteronism in a predominantly female cohort of normotensive individuals: a very high odds ratio for progression into arterial hypertension. J Clin Endocrinol Metab 2013; 98:1409&#x2013;1416.</Citation><ArticleIdList><ArticleId IdType="pubmed">23471976</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown JM, Robinson-Cohen C, Luque-Fernandez MA, Allison MA, Baudrand R, Ix JH, Kestenbaum B, de Boer IH, Vaidya A. The spectrum of subclinical primary aldosteronism and incident hypertension. Ann Intern Med 2017; 167:630&#x2013;641.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5920695</ArticleId><ArticleId IdType="pubmed">29052707</ArticleId></ArticleIdList></Reference><Reference><Citation>Baudrand R, Guarda FJ, Fardella CE, Hundemer G, Brown J, Williams GH, Vaidya A. Continuum of renin-independent aldosteronism in normotension. Hypertension 2017; 69:950&#x2013;956.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5391287</ArticleId><ArticleId IdType="pubmed">28289182</ArticleId></ArticleIdList></Reference><Reference><Citation>Inoue K, Goldwater D, Allison M, Seeman T, Kestenbaum BR, Watson KE. Serum aldosterone concentration, blood pressure, and coronary artery calcium: the multi-ethnic study of atherosclerosis. Hypertension 2020; 76:113&#x2013;120.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10681368</ArticleId><ArticleId IdType="pubmed">32418495</ArticleId></ArticleIdList></Reference><Reference><Citation>Monticone S, Burrello J, Tizzani D, Bertello C, Viola A, Buffolo F, Gabetti L, Mengozzi G, Williams TA, Rabbia F, Veglio F, Mulatero P. Prevalence and clinical manifestations of primary aldosteronism encountered in primary care practice. J Am Coll Cardiol 2017; 69:1811&#x2013;1820.</Citation><ArticleIdList><ArticleId IdType="pubmed">28385310</ArticleId></ArticleIdList></Reference><Reference><Citation>Baudrand R, Guarda FJ, Torrey J, Williams G, Vaidya A. Dietary sodium restriction increases the risk of misinterpreting mild cases of primary aldosteronism. J Clin Endocrinol Metab 2016; 101:3989&#x2013;3996.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5095258</ArticleId><ArticleId IdType="pubmed">27428770</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaidya A, Mulatero P, Baudrand R, Adler GK. The expanding spectrum of primary aldosteronism: implications for diagnosis, pathogenesis, and treatment. Endocr Rev 2018; 39:1057&#x2013;1088.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6260247</ArticleId><ArticleId IdType="pubmed">30124805</ArticleId></ArticleIdList></Reference><Reference><Citation>Galati S-J, Cheesman KC, Springer-Miller R, Hopkins SM, Krakoff L, Bagiella E, Zhuk RA, Ying TK, Amer C, Boyajian MK, Inabnet WB, Levine AC. Prevalence of primary aldosteronism in an urban hypertensive population. Endocr Pract 2016; 22:1296&#x2013;1302.</Citation><ArticleIdList><ArticleId IdType="pubmed">27893293</ArticleId></ArticleIdList></Reference><Reference><Citation>Libianto R, Russell GM, Stowasser M, Gwini SM, Nuttall P, Shen J, Young MJ, Fuller PJ, Yang J. Detecting primary aldosteronism in Australian primary care: a prospective study. Med J Aust 2022; 216:408&#x2013;412.</Citation><ArticleIdList><ArticleId IdType="pubmed">35218017</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu Z, Yang J, Hu J, Song Y, He W, Luo T, Cheng Q, Ma L, Luo R, Fuller PJ, Cai J, Li Q, Yang S, Mei M, Luo S, Liao K, Zhang Y, He Y, He Y, Xiao M, Peng B. Primary aldosteronism in patients in China with recently detected hypertension. J Am Coll Cardiol 2020; 75:1913&#x2013;1922.</Citation><ArticleIdList><ArticleId IdType="pubmed">32327102</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon RD, Stowasser M, Tunny TJ, Klemm SA, Rutherford JC. High incidence of primary aldosteronism in 199 patients referred with hypertension. Clin Exp Pharmacol Physiol 1994; 21:315&#x2013;318.</Citation><ArticleIdList><ArticleId IdType="pubmed">7923898</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwartz GL, Chapman AB, Boerwinkle E, Kisabeth RM, Turner ST. Screening for primary aldosteronism: implications of an increased plasma aldosterone/renin ratio. Clin Chem 2002; 48:1919&#x2013;1923.</Citation><ArticleIdList><ArticleId IdType="pubmed">12406976</ArticleId></ArticleIdList></Reference><Reference><Citation>Burrello J, Monticone S, Losano I, Cavaglia G, Buffolo F, Tetti M, Covella M, Rabbia F, Veglio F, Pasini B, Williams TA, Mulatero P. Prevalence of hypokalemia and primary aldosteronism in 5100 patients referred to a tertiary hypertension unit. Hypertension 2020; 75:1025&#x2013;1033. doi:10.1161/HYPERTENSIONAHA.119.14063</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/HYPERTENSIONAHA.119.14063</ArticleId><ArticleId IdType="pubmed">32114853</ArticleId></ArticleIdList></Reference><Reference><Citation>Mulatero P, Stowasser M, Loh KC, Fardella CE, Gordon RD, Mosso L, Gomez-Sanchez CE, Veglio F, Young WF. Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents. J Clin Endocrinol Metab 2004; 89:1045&#x2013;1050.</Citation><ArticleIdList><ArticleId IdType="pubmed">15001583</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossi GP, Bernini G, Caliumi C, Desideri G, Fabris B, Ferri C, Ganzaroli C, Giacchetti G, Letizia C, Maccario M, Mallamaci F, Mannelli M, Mattarello MJ, Moretti A, Palumbo G, Parenti G, Porteri E, Semplicini A, Rizzoni D, Rossi E, Boscaro M, Pessina AC, Mantero F, Investigators PS. A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. J Am Coll Cardiol 2006; 48:2293&#x2013;2300.</Citation><ArticleIdList><ArticleId IdType="pubmed">17161262</ArticleId></ArticleIdList></Reference><Reference><Citation>Calhoun DA, Nishizaka MK, Zaman MA, Thakkar RB, Weissmann P. Hyperaldosteronism among black and white subjects with resistant hypertension. Hypertension 2002; 40:892&#x2013;896.</Citation><ArticleIdList><ArticleId IdType="pubmed">12468575</ArticleId></ArticleIdList></Reference><Reference><Citation>Douma S, Petidis K, Doumas M, Papaefthimiou P, Triantafyllou A, Kartali N, Papadopoulos N, Vogiatzis K, Zamboulis C. Prevalence of primary hyperaldosteronism in resistant hypertension: a retrospective observational study. Lancet 2008; 371:1921&#x2013;1926.</Citation><ArticleIdList><ArticleId IdType="pubmed">18539224</ArticleId></ArticleIdList></Reference><Reference><Citation>Parasiliti-Caprino M, Lopez C, Prencipe N, Lucatello B, Settanni F, Giraudo G, Rossato D, Mengozzi G, Ghigo E, Benso A, Maccario M. Prevalence of primary aldosteronism and association with cardiovascular complications in patients with resistant and refractory hypertension. J Hypertens 2020; 38:1841&#x2013;1848.</Citation><ArticleIdList><ArticleId IdType="pubmed">32384388</ArticleId></ArticleIdList></Reference><Reference><Citation>Memon SS, Lila A, Barnabas R, Goroshi M, Sarathi V, Shivane V, Patil V, Shah N, Bandgar T. Prevalence of primary aldosteronism in type 2 diabetes mellitus and hypertension: a prospective study from Western India. Clin Endocrinol 2022; 96:539&#x2013;548.</Citation><ArticleIdList><ArticleId IdType="pubmed">34580897</ArticleId></ArticleIdList></Reference><Reference><Citation>Voulgaris N, Tyfoxylou E, Vlachou S, Kyriazi E, Gravvanis C, Kapsali C, Markou A, Papanastasiou L, Gryparis A, Kassi E, Chrousos G, Kaltsas G, Piaditis G. Prevalence of primary aldosteronism across the stages of hypertension based on a new combined overnight test. Horm Metab Res 2021; 53:461&#x2013;469.</Citation><ArticleIdList><ArticleId IdType="pubmed">34282597</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu Y, Zhang J, Liu W, Su X. Determining the prevalence of primary aldosteronism in patients with new-onset type 2 diabetes and hypertension. J Clin Endocrinol Metab 2020; 105:1079&#x2013;1085. doi:10.1210/clinem/dgz293</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/clinem/dgz293</ArticleId><ArticleId IdType="pubmed">32163576</ArticleId></ArticleIdList></Reference><Reference><Citation>Hung CS, Chou CH, Liao CW, Lin YT, Wu XM, Chang YY, Chen YH, Wu VC, Su MJ, Ho YL, Chen MF, Wu KD, Lin YH; TAIPAI Study Group. Aldosterone induces tissue inhibitor of metalloproteinases-1 expression and further contributes to collagen accumulation: from clinical to bench studies. Hypertension 2016; 67:1309&#x2013;1320.</Citation><ArticleIdList><ArticleId IdType="pubmed">27113051</ArticleId></ArticleIdList></Reference><Reference><Citation>Hung CS, Sung SH, Liao CW, Pan CT, Chang CC, Chen ZW, Wu VC, Chen CH, Cheng HM, Lin YH; TAIPAI Study Group. Aldosterone induces vascular damage. Hypertension 2019; 74:623&#x2013;629.</Citation><ArticleIdList><ArticleId IdType="pubmed">31352825</ArticleId></ArticleIdList></Reference><Reference><Citation>Bernini G, Galetta F, Franzoni F, Bardini M, Taurino C, Bernardini M, Ghiadoni L, Bernini M, Santoro G, Salvetti A. Arterial stiffness, intima-media thickness and carotid artery fibrosis in patients with primary aldosteronism. J Hypertens 2008; 26:2399&#x2013;2405.</Citation><ArticleIdList><ArticleId IdType="pubmed">19008719</ArticleId></ArticleIdList></Reference><Reference><Citation>Demirkiran A, Everaars H, Elitok A, van de Ven PM, Smulders YM, Dreijerink KM, Tanakol R, Ozcan M. Hypertension with primary aldosteronism is associated with increased carotid intima-media thickness and endothelial dysfunction. J Clin Hypertens 2019; 21:932&#x2013;941.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6771730</ArticleId><ArticleId IdType="pubmed">31187936</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen ZW, Tsai CH, Pan CT, Chou CH, Liao CW, Hung CS, Wu VC, Lin YH; TAIPAI Study Group. Endothelial dysfunction in primary aldosteronism. Int J Mol Sci 2019; 20. doi:10.3390/ijms20205214</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms20205214</ArticleId><ArticleId IdType="pmc">PMC6829211</ArticleId><ArticleId IdType="pubmed">31640178</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Heijden C, Smeets EMM, Aarntzen E, Noz MP, Monajemi H, Kersten S, Kaffa C, Hoischen A, Deinum J, Joosten LAB, Netea MG, Riksen NP. Arterial wall inflammation and increased hematopoietic activity in patients with primary aldosteronism. J Clin Endocrinol Metab 2020; 105:e1967&#x2013;e1980. doi:10.1210/clinem/dgz306</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/clinem/dgz306</ArticleId><ArticleId IdType="pmc">PMC7105350</ArticleId><ArticleId IdType="pubmed">31875423</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsai CH, Pan CT, Chang YY, Chen ZW, Wu VC, Hung CS, Lin YH. Left ventricular remodeling and dysfunction in primary aldosteronism. J Hum Hypertens 2021; 35:131&#x2013;147.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7895762</ArticleId><ArticleId IdType="pubmed">33067554</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossi GP, Seccia TM, Maiolino G, Cesari M. The cardiovascular consequences of hyperaldosteronism. Ann Endocrinol 2021; 82:174&#x2013;178.</Citation><ArticleIdList><ArticleId IdType="pubmed">32192789</ArticleId></ArticleIdList></Reference><Reference><Citation>Briet M, Barhoumi T, Mian MOR, Coelho SC, Ouerd S, Rautureau Y, Coffman TM, Paradis P, Schiffrin EL. Aldosterone-induced vascular remodeling and endothelial dysfunction require functional angiotensin type 1a receptors. Hypertension 2016; 67:897&#x2013;905.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4833572</ArticleId><ArticleId IdType="pubmed">27045029</ArticleId></ArticleIdList></Reference><Reference><Citation>Briet M, Schiffrin EL. Vascular actions of aldosterone. J Vasc Res 2013; 50:89&#x2013;99.</Citation><ArticleIdList><ArticleId IdType="pubmed">23172373</ArticleId></ArticleIdList></Reference><Reference><Citation>Diaz-Otero JM, Fisher C, Downs K, Moss ME, Jaffe IZ, Jackson WF, Dorrance AM. Endothelial mineralocorticoid receptor mediates parenchymal arteriole and posterior cerebral artery remodeling during angiotensin II-induced hypertension. Hypertension 2017; 70:1113&#x2013;1121.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5680120</ArticleId><ArticleId IdType="pubmed">28974571</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim SK, McCurley AT, DuPont JJ, Aronovitz M, Moss ME, Stillman IE, Karumanchi SA, Christou DD, Jaffe IZ. Smooth muscle cell-mineralocorticoid receptor as a mediator of cardiovascular stiffness with aging. Hypertension 2018; 71:609&#x2013;621.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5843545</ArticleId><ArticleId IdType="pubmed">29463624</ArticleId></ArticleIdList></Reference><Reference><Citation>McCurley A, Pires PW, Bender SB, Aronovitz M, Zhao MJ, Metzger D, Chambon P, Hill MA, Dorrance AM, Mendelsohn ME, Jaffe IZ. Direct regulation of blood pressure by smooth muscle cell mineralocorticoid receptors. Nat Med 2012; 18:1429&#x2013;1433.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3491085</ArticleId><ArticleId IdType="pubmed">22922412</ArticleId></ArticleIdList></Reference><Reference><Citation>Mueller KB, Bender SB, Hong K, Yang Y, Aronovitz M, Jaisser F, Hill MA, Jaffe IZ. Endothelial mineralocorticoid receptors differentially contribute to coronary and mesenteric vascular function without modulating blood pressure. Hypertension 2015; 66:988&#x2013;997.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4600033</ArticleId><ArticleId IdType="pubmed">26351033</ArticleId></ArticleIdList></Reference><Reference><Citation>Tesch GH, Young MJ. Mineralocorticoid receptor signaling as a therapeutic target for renal and cardiac fibrosis. Front Pharmacol 2017; 8:313.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5447060</ArticleId><ArticleId IdType="pubmed">28611666</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossi GP, Bolognesi M, Rizzoni D, Seccia TM, Piva A, Porteri E, Tiberio GA, Giulini SM, Agabiti-Rosei E, Pessina AC. Vascular remodeling and duration of hypertension predict outcome of adrenalectomy in primary aldosteronism patients. Hypertension 2008; 51:1366&#x2013;1371.</Citation><ArticleIdList><ArticleId IdType="pubmed">18347224</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossi GP, Cesari M, Pessina AC. Left ventricular changes in primary aldosteronism. Am J Hypertens 2003; 16:96&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pubmed">12517694</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossi GP, Di Bello V, Ganzaroli C, Sacchetto A, Cesari M, Bertini A, Giorgi D, Scognamiglio R, Mariani M, Pessina AC. Excess aldosterone is associated with alterations of myocardial texture in primary aldosteronism. Hypertension 2002; 40:23&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="pubmed">12105133</ArticleId></ArticleIdList></Reference><Reference><Citation>Rocha R, Stier CT Jr, Kifor I, Ochoa-Maya MR, Rennke HG, Williams GH, Adler GK. Aldosterone: a mediator of myocardial necrosis and renal arteriopathy. Endocrinology 2000; 141:3871&#x2013;3878.</Citation><ArticleIdList><ArticleId IdType="pubmed">11014244</ArticleId></ArticleIdList></Reference><Reference><Citation>Martinez DV, Rocha R, Matsumura M, Oestreicher E, Ochoa-Maya M, Roubsanthisuk W, Williams GH, Adler GK. Cardiac damage prevention by eplerenone: comparison with low sodium diet or potassium loading. Hypertension 2002; 39:614&#x2013;618.</Citation><ArticleIdList><ArticleId IdType="pubmed">11882618</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaddam K, Corros C, Pimenta E, Ahmed M, Denney T, Aban I, Inusah S, Gupta H, Lloyd SG, Oparil S, Husain A, Dell&#x2019;Italia LJ, Calhoun DA. Rapid reversal of left ventricular hypertrophy and intracardiac volume overload in patients with resistant hypertension and hyperaldosteronism: a prospective clinical study. Hypertension 2010; 55:1137&#x2013;1142.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2864599</ArticleId><ArticleId IdType="pubmed">20351345</ArticleId></ArticleIdList></Reference><Reference><Citation>Redheuil A, Blanchard A, Pereira H, Raissouni Z, Lorthioir A, Soulat G, Vargas-Poussou R, Amar L, Paul JL, Helley D, Azizi M, Kachenoura N, Mousseaux E. Aldosterone-related myocardial extracellular matrix expansion in hypertension in humans: a proof-of-concept study by cardiac magnetic resonance. JACC Cardiovasc Imaging 2020; 13:2149&#x2013;2159.</Citation><ArticleIdList><ArticleId IdType="pubmed">32950448</ArticleId></ArticleIdList></Reference><Reference><Citation>Catena C, Colussi G, Nadalini E, Chiuch A, Baroselli S, Lapenna R, Sechi LA. Cardiovascular outcomes in patients with primary aldosteronism after treatment. Arch Intern Med 2008; 168:80&#x2013;85.</Citation><ArticleIdList><ArticleId IdType="pubmed">18195199</ArticleId></ArticleIdList></Reference><Reference><Citation>Milliez P, Girerd X, Plouin PF, Blacher J, Safar ME, Mourad JJ. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol 2005; 45:1243&#x2013;1248.</Citation><ArticleIdList><ArticleId IdType="pubmed">15837256</ArticleId></ArticleIdList></Reference><Reference><Citation>Mulatero P, Monticone S, Bertello C, Viola A, Tizzani D, Iannaccone A, Crudo V, Burrello J, Milan A, Rabbia F, Veglio F. Long-term cardio- and cerebrovascular events in patients with primary aldosteronism. J Clin Endocrinol Metab 2013; 98:4826&#x2013;4833.</Citation><ArticleIdList><ArticleId IdType="pubmed">24057288</ArticleId></ArticleIdList></Reference><Reference><Citation>Savard S, Amar L, Plouin PF, Steichen O. Cardiovascular complications associated with primary aldosteronism: a controlled cross-sectional study. Hypertension 2013; 62:331&#x2013;336.</Citation><ArticleIdList><ArticleId IdType="pubmed">23753408</ArticleId></ArticleIdList></Reference><Reference><Citation>Murata M, Kitamura T, Tamada D, Mukai K, Kurebayashi S, Yamamoto T, Hashimoto K, Hayashi RD, Kouhara H, Takeiri S, Kajimoto Y, Nakao M, Hamasaki T, Otsuki M, Shimomura I. Plasma aldosterone level within the normal range is less associated with cardiovascular and cerebrovascular risk in primary aldosteronism. J Hypertens 2017; 35:1079&#x2013;1085.</Citation><ArticleIdList><ArticleId IdType="pubmed">28129245</ArticleId></ArticleIdList></Reference><Reference><Citation>Takeda R, Matsubara T, Miyamori I, Hatakeyama H, Morise T. Vascular complications in patients with aldosterone producing adenoma in Japan: comparative study with essential hypertension. The Research Committee of Disorders of Adrenal Hormones in Japan. J Endocrinol Invest 1995; 18:370&#x2013;373.</Citation><ArticleIdList><ArticleId IdType="pubmed">7594226</ArticleId></ArticleIdList></Reference><Reference><Citation>Reincke M, Fischer E, Gerum S, Merkle K, Schulz S, Pallauf A, Quinkler M, Hanslik G, Lang K, Hahner S, Allolio B, Meisinger C, Holle R, Beuschlein F, Bidlingmaier M, Endres S; German Conn&#x2019;s Registry-Else Kroner-Fresenius-Hyperaldosteronism Registry. Observational study mortality in treated primary aldosteronism: the German Conn&#x2019;s registry. Hypertension 2012; 60:618&#x2013;624.</Citation><ArticleIdList><ArticleId IdType="pubmed">22824982</ArticleId></ArticleIdList></Reference><Reference><Citation>Hundemer GL, Curhan GC, Yozamp N, Wang M, Vaidya A. Incidence of atrial fibrillation and mineralocorticoid receptor activity in patients with medically and surgically treated primary aldosteronism. JAMA Cardiol 2018; 3:768&#x2013;774.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6143072</ArticleId><ArticleId IdType="pubmed">30027227</ArticleId></ArticleIdList></Reference><Reference><Citation>Hundemer GL, Curhan GC, Yozamp N, Wang M, Vaidya A. Cardiometabolic outcomes and mortality in medically treated primary aldosteronism: a retrospective cohort study. Lancet Diabetes Endocrinol 2018; 6:51&#x2013;59.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5953512</ArticleId><ArticleId IdType="pubmed">29129576</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu VC, Wang SM, Chang CH, Hu YH, Lin LY, Lin YH, Chueh SC, Chen L, Wu KD. Long term outcome of aldosteronism after target treatments. Sci Rep 2016; 6:32103.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5009379</ArticleId><ArticleId IdType="pubmed">27586402</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossi GP, Sacchetto A, Pavan E, Scognamiglio R, Pietra M, Pessina AC. Left ventricular systolic function in primary aldosteronism and hypertension. J Hypertens 1998; 16:2075&#x2013;2077.</Citation><ArticleIdList><ArticleId IdType="pubmed">9886899</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossi GP, Sacchetto A, Visentin P, Canali C, Graniero GR, Palatini P, Pessina AC. Changes in left ventricular anatomy and function in hypertension and primary aldosteronism. Hypertension 1996; 27:1039&#x2013;1045.</Citation><ArticleIdList><ArticleId IdType="pubmed">8621194</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossi GP, Maiolino G, Flego A, Belfiore A, Bernini G, Fabris B, Ferri C, Giacchetti G, Letizia C, Maccario M, Mallamaci F, Muiesan ML, Mannelli M, Negro A, Palumbo G, Parenti G, Rossi E, Mantero F, Investigators PS. Adrenalectomy lowers incident atrial fibrillation in primary aldosteronism patients at long term. Hypertension 2018; 71:585&#x2013;591.</Citation><ArticleIdList><ArticleId IdType="pubmed">29483224</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohno Y, Sone M, Inagaki N, Yamasaki T, Ogawa O, Takeda Y, Kurihara I, Itoh H, Umakoshi H, Tsuiki M, Ichijo T, Katabami T, Tanaka Y, Wada N, Shibayama Y, Yoshimoto T, Ogawa Y, Kawashima J, Takahashi K, Fujita M, Watanabe M, Matsuda Y, Kobayashi H, Shibata H, Kamemura K, Otsuki M, Fujii Y, Yamamoto K, Ogo A, Okamura S, Miyauchi S, Fukuoka T, Izawa S, Yoneda T, Hashimoto S, Yanase T, Suzuki T, Kawamura T, Tabara Y, Matsuda F, Naruse M; Nagahama Study; JPAS Study Group. Prevalence of cardiovascular disease and its risk factors in primary aldosteronism: a multicenter study in Japan. Hypertension 2018; 71:530&#x2013;537.</Citation><ArticleIdList><ArticleId IdType="pubmed">29358460</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossi GP, Cesari M, Cuspidi C, Maiolino G, Cicala MV, Bisogni V, Mantero F, Pessina AC. Long-term control of arterial hypertension and regression of left ventricular hypertrophy with treatment of primary aldosteronism. Hypertension 2013; 62:62&#x2013;69.</Citation><ArticleIdList><ArticleId IdType="pubmed">23648698</ArticleId></ArticleIdList></Reference><Reference><Citation>Monticone S, D&#x2019;Ascenzo F, Moretti C, Williams TA, Veglio F, Gaita F, Mulatero P. Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis. Lancet Diabetes Endocrinol 2018; 6:41&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pubmed">29129575</ArticleId></ArticleIdList></Reference><Reference><Citation>Ribstein J, Du Cailar G, Fesler P, Mimran A. Relative glomerular hyperfiltration in primary aldosteronism. J Am Soc Nephrol 2005; 16:1320&#x2013;1325.</Citation><ArticleIdList><ArticleId IdType="pubmed">15800124</ArticleId></ArticleIdList></Reference><Reference><Citation>Hundemer GL, Baudrand R, Brown JM, Curhan G, Williams GH, Vaidya A. Renin phenotypes characterize vascular disease, autonomous aldosteronism, and mineralocorticoid receptor activity. J Clin Endocrinol Metab 2017; 102:1835&#x2013;1843.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5470762</ArticleId><ArticleId IdType="pubmed">28323995</ArticleId></ArticleIdList></Reference><Reference><Citation>Hundemer GL, Curhan GC, Yozamp N, Wang M, Vaidya A. Renal outcomes in medically and surgically treated primary aldosteronism. Hypertension 2018; 72:658&#x2013;666.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6202119</ArticleId><ArticleId IdType="pubmed">29987110</ArticleId></ArticleIdList></Reference><Reference><Citation>Reincke M, Rump LC, Quinkler M, Hahner S, Diederich S, Lorenz R, Seufert J, Schirpenbach C, Beuschlein F, Bidlingmaier M, Meisinger C, Holle R, Endres S; Participants of German Conn&#x2019;s Registry. Risk factors associated with a low glomerular filtration rate in primary aldosteronism. J Clin Endocrinol Metab 2009; 94:869&#x2013;875.</Citation><ArticleIdList><ArticleId IdType="pubmed">19116235</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossi GP, Bernini G, Desideri G, Fabris B, Ferri C, Giacchetti G, Letizia C, Maccario M, Mannelli M, Matterello MJ, Montemurro D, Palumbo G, Rizzoni D, Rossi E, Pessina AC, Mantero F; PAPY Study Participants. Renal damage in primary aldosteronism: results of the PAPY Study. Hypertension 2006; 48:232&#x2013;238.</Citation><ArticleIdList><ArticleId IdType="pubmed">16801482</ArticleId></ArticleIdList></Reference><Reference><Citation>Sechi LA, Novello M, Lapenna R, Baroselli S, Nadalini E, Colussi GL, Catena C. Long-term renal outcomes in patients with primary aldosteronism. JAMA 2006; 295:2638&#x2013;2645.</Citation><ArticleIdList><ArticleId IdType="pubmed">16772627</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu VC, Kuo CC, Wang SM, Liu KL, Huang KH, Lin YH, Chu TS, Chang HW, Lin CY, Tsai CT, Lin LY, Chueh SC, Kao TW, Chen YM, Chiang WC, Tsai TJ, Ho YL, Lin SL, Wang WJ, Wu KD; TAIPAI Study Group. Primary aldosteronism: changes in cystatin C-based kidney filtration, proteinuria, and renal duplex indices with treatment. J Hypertens 2011; 29:1778&#x2013;1786.</Citation><ArticleIdList><ArticleId IdType="pubmed">21738054</ArticleId></ArticleIdList></Reference><Reference><Citation>Kobayashi Y, Haze T, Yano Y, Tamura K, Kurihara I, Ichijo T, Yoneda T, Katabami T, Tsuiki M, Wada N, Ogawa Y, Kawashima J, Sone M, Inagaki N, Yamada T, Okamoto R, Fujita M, Kamemura K, Yamamoto K, Izawa S, Tanabe A, Naruse M; JPAS/JRAS Study Group. Associations between changes in plasma renin activity and aldosterone concentrations and changes in kidney function after treatment for primary aldosteronism. Kidney Int Rep 2020; 5:1291&#x2013;1297.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7403537</ArticleId><ArticleId IdType="pubmed">32775828</ArticleId></ArticleIdList></Reference><Reference><Citation>Monticone S, Sconfienza E, D&#x2019;Ascenzo F, Buffolo F, Satoh F, Sechi LA, Veglio F, Mulatero P. Renal damage in primary aldosteronism: a systematic review and meta-analysis. J Hypertens 2020; 38:3&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">31385870</ArticleId></ArticleIdList></Reference><Reference><Citation>Arlt W, Lang K, Sitch AJ, Dietz AS, Rhayem Y, Bancos I, Feuchtinger A, Chortis V, Gilligan LC, Ludwig P, Riester A, Asbach E, Hughes BA, O&#x2019;Neil DM, Bidlingmaier M, Tomlinson JW, Hassan-Smith ZK, Rees DA, Adolf C, Hahner S, Quinkler M, Dekkers T, Deinum J, Biehl M, Keevil BG, Shackleton CH, Deeks JJ, Walch AK, Beuschlein F, Reincke M. Steroid metabolome analysis reveals prevalent glucocorticoid excess in primary aldosteronism. JCI Insight 2017; 2:e93136. doi:10.1172/jci.insight.93136</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.93136</ArticleId><ArticleId IdType="pmc">PMC5396526</ArticleId><ArticleId IdType="pubmed">28422753</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen W, Li F, He C, Zhu Y, Tan W. Elevated prevalence of abnormal glucose metabolism in patients with primary aldosteronism: a meta-analysis. Ir J Med Sci 2014; 183:283&#x2013;291.</Citation><ArticleIdList><ArticleId IdType="pubmed">23990176</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanslik G, Wallaschofski H, Dietz A, Riester A, Reincke M, Allolio B, Lang K, Quack I, Rump LC, Willenberg HS, Beuschlein F, Quinkler M, Hannemann A; Participants of the German Conn&#x2019;s Registry. Increased prevalence of diabetes mellitus and the metabolic syndrome in patients with primary aldosteronism of the German Conn&#x2019;s Registry. Eur J Endocrinol 2015; 173:665&#x2013;675.</Citation><ArticleIdList><ArticleId IdType="pubmed">26311088</ArticleId></ArticleIdList></Reference><Reference><Citation>Fallo F, Veglio F, Bertello C, Sonino N, Della Mea P, Ermani M, Rabbia F, Federspil G, Mulatero P. Prevalence and characteristics of the metabolic syndrome in primary aldosteronism. J Clin Endocrinol Metab 2006; 91:454&#x2013;459.</Citation><ArticleIdList><ArticleId IdType="pubmed">16291704</ArticleId></ArticleIdList></Reference><Reference><Citation>Adler GK, Murray GR, Turcu AF, Nian H, Yu C, Solorzano CC, Manning R, Peng D, Luther JM. Primary aldosteronism decreases insulin secretion and increases insulin clearance in humans. Hypertension 2020; 75:1251&#x2013;1259.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7155918</ArticleId><ArticleId IdType="pubmed">32172621</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonzaga CC, Gaddam KK, Ahmed MI, Pimenta E, Thomas SJ, Harding SM, Oparil S, Cofield SS, Calhoun DA. Severity of obstructive sleep apnea is related to aldosterone status in subjects with resistant hypertension. J Clin Sleep Med 2010; 6:363&#x2013;368.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2919667</ArticleId><ArticleId IdType="pubmed">20726285</ArticleId></ArticleIdList></Reference><Reference><Citation>Pimenta E, Stowasser M, Gordon RD, Harding SM, Batlouni M, Zhang B, Oparil S, Calhoun DA. Increased dietary sodium is related to severity of obstructive sleep apnea in patients with resistant hypertension and hyperaldosteronism. Chest 2013; 143:978&#x2013;983.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3616687</ArticleId><ArticleId IdType="pubmed">23288434</ArticleId></ArticleIdList></Reference><Reference><Citation>Pratt-Ubunama MN, Nishizaka MK, Boedefeld RL, Cofield SS, Harding SM, Calhoun DA. Plasma aldosterone is related to severity of obstructive sleep apnea in subjects with resistant hypertension. Chest 2007; 131:453&#x2013;459.</Citation><ArticleIdList><ArticleId IdType="pubmed">17296647</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Murro A, Petramala L, Cotesta D, Zinnamosca L, Crescenzi E, Marinelli C, Saponara M, Letizia C. Renin-angiotensin-aldosterone system in patients with sleep apnoea: prevalence of primary aldosteronism. J Renin Angiotensin Aldosterone Syst 2010; 11:165&#x2013;172.</Citation><ArticleIdList><ArticleId IdType="pubmed">20488824</ArticleId></ArticleIdList></Reference><Reference><Citation>Chee MR, Hoo J, Libianto R, Gwini SM, Hamilton G, Narayan O, Young MJ, Fuller PJ, Yang J. Prospective screening for primary aldosteronism in patients with suspected obstructive sleep apnea. Hypertension 2021; 77:2094&#x2013;2103.</Citation><ArticleIdList><ArticleId IdType="pubmed">33896193</ArticleId></ArticleIdList></Reference><Reference><Citation>Dobrowolski P, Kolodziejczyk-Kruk S, Warchol-Celinska E, Kabat M, Ambroziak U, Wrobel A, Piekarczyk P, Ostrowska A, Januszewicz M, Sliwinski P, Lenders JWM, Januszewicz A, Prejbisz A. Primary aldosteronism is highly prevalent in patients with hypertension and moderate to severe obstructive sleep apnea. J Clin Sleep Med 2021; 17:629&#x2013;637.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8020703</ArticleId><ArticleId IdType="pubmed">33135629</ArticleId></ArticleIdList></Reference><Reference><Citation>Salcuni AS, Carnevale V, Battista C, Palmieri S, Eller-Vainicher C, Guarnieri V, Pugliese F, Guglielmi G, Desina G, Minisola S, Chiodini I, Scillitani A. Primary aldosteronism as a cause of secondary osteoporosis. Eur J Endocrinol 2017; 177:431&#x2013;437.</Citation><ArticleIdList><ArticleId IdType="pubmed">28794160</ArticleId></ArticleIdList></Reference><Reference><Citation>Salcuni AS, Palmieri S, Carnevale V, Morelli V, Battista C, Guarnieri V, Guglielmi G, Desina G, Eller-Vainicher C, Beck-Peccoz P, Scillitani A, Chiodini I. Bone involvement in aldosteronism. J Bone Miner Res 2012; 27:2217&#x2013;2222.</Citation><ArticleIdList><ArticleId IdType="pubmed">22589146</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu VC, Chang CH, Wang CY, Lin YH, Kao TW, Lin PC, Chu TS, Chang YS, Chen L, Wu KD, Chueh SJ. Risk of fracture in primary aldosteronism: a population-based cohort study. J Bone Miner Res 2017; 32:743&#x2013;752.</Citation><ArticleIdList><ArticleId IdType="pubmed">27862274</ArticleId></ArticleIdList></Reference><Reference><Citation>Bayomy O, Zaheer S, Williams JS, Curhan G, Vaidya A. Disentangling the relationships between the renin-angiotensin-aldosterone system, calcium physiology, and risk for kidney stones. J Clin Endocrinol Metab 2020; 105:1937&#x2013;1946. doi:10.1210/clinem/dgaa123</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/clinem/dgaa123</ArticleId><ArticleId IdType="pmc">PMC7185954</ArticleId><ArticleId IdType="pubmed">32163150</ArticleId></ArticleIdList></Reference><Reference><Citation>Joseph JJ, Pohlman NK, Zhao S, Kline D, Brock G, Echouffo-Tcheugui JB, Sims M, Effoe VS, Wu WC, Kalyani RR, Wand GS, Kluwe B, Hsueh WA, Abdalla M, Shimbo D, Golden SH. Association of serum aldosterone and plasma renin activity with ambulatory blood pressure in African Americans: the Jackson Heart Study. Circulation 2021; 143:2355&#x2013;2366.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8789344</ArticleId><ArticleId IdType="pubmed">33605160</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu J, Shen H, Huo P, Yang J, Fuller PJ, Wang K, Yang Y, Ma L, Cheng Q, Gong L, He W, Luo T, Mei M, Wang Y, Du Z, Luo R, Cai J, Li Q, Song Y, Yang S. Heightened cardiovascular risk in hypertension associated with renin-independent aldosteronism versus renin-dependent aldosteronism: a collaborative study. J Am Heart Assoc 2021; 10:e023082.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9075265</ArticleId><ArticleId IdType="pubmed">34889107</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown JM, Wijkman M, Claggett B, Shah A, Ballantyne C, Coresh J, Grams M, Wang Z, Yu B, Boerwinkle E, Vaidya A, Solomon S. Cardiac structure and function across the spectrum of aldosteronism: the atherosclerosis risk in communities study. Hypertension 2022; e-pub ahead of print.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9759338</ArticleId><ArticleId IdType="pubmed">35582954</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown JM, Underwood PC, Ferri C, Hopkins PN, Williams GH, Adler GK, Vaidya A. Aldosterone dysregulation with aging predicts renal vascular function and cardiovascular risk. Hypertension 2014; 63:1205&#x2013;1211.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4016103</ArticleId><ArticleId IdType="pubmed">24664291</ArticleId></ArticleIdList></Reference><Reference><Citation>Verma A, Vaidya A, Subudhi S, Waikar S. Aldosterone in chronic kidney disease and renal outcomes. Eur Heart J 2022, in press.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10147385</ArticleId><ArticleId IdType="pubmed">36219773</ArticleId></ArticleIdList></Reference><Reference><Citation>Funder JW, Carey RM, Mantero F, Murad MH, Reincke M, Shibata H, Stowasser M, Young WF Jr. The management of primary aldosteronism: case detection, diagnosis, and treatment: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2016; 101:1889&#x2013;1916.</Citation><ArticleIdList><ArticleId IdType="pubmed">26934393</ArticleId></ArticleIdList></Reference><Reference><Citation>Mulatero P, Monticone S, Deinum J, Amar L, Prejbisz A, Zennaro MC, Beuschlein F, Rossi GP, Nishikawa T, Morganti A, Seccia TM, Lin YH, Fallo F, Widimsky J. Genetics, prevalence, screening and confirmation of primary aldosteronism: a position statement and consensus of the Working Group on Endocrine Hypertension of The European Society of Hypertension. J Hypertens 2020; 38:1919&#x2013;1928.</Citation><ArticleIdList><ArticleId IdType="pubmed">32890264</ArticleId></ArticleIdList></Reference><Reference><Citation>Reincke M, Bancos I, Mulatero P, Scholl UI, Stowasser M, Williams TA. Diagnosis and treatment of primary aldosteronism. Lancet Diabetes Endocrinol 2021; 9:876&#x2013;892.</Citation><ArticleIdList><ArticleId IdType="pubmed">34798068</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaffe G, Gray Z, Krishnan G, Stedman M, Zheng Y, Han J, Chertow GM, Leppert JT, Bhalla V. Screening rates for primary aldosteronism in resistant hypertension: a cohort study. Hypertension 2020; 75:650&#x2013;659.</Citation><ArticleIdList><ArticleId IdType="pubmed">32008436</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruhle BC, White MG, Alsafran S, Kaplan EL, Angelos P, Grogan RH. Keeping primary aldosteronism in mind: deficiencies in screening at-risk hypertensives. Surgery 2019; 165:221&#x2013;227.</Citation><ArticleIdList><ArticleId IdType="pubmed">30415872</ArticleId></ArticleIdList></Reference><Reference><Citation>Sivarajah M, Beninato T, Fahey TJ III. Adherence to consensus guidelines for screening of primary aldosteronism in an urban healthcare system. Surgery 2020; 167:211&#x2013;215.</Citation><ArticleIdList><ArticleId IdType="pubmed">31564486</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu YY, King J, Kline GA, Padwal RS, Pasieka JL, Chen G, So B, Harvey A, Chin A, Leung AA. Outcomes of a specialized clinic on rates of investigation and treatment of primary aldosteronism. JAMA Surg 2021; 156:541&#x2013;549. doi:10.1001/jamasurg.2021.0254</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamasurg.2021.0254</ArticleId><ArticleId IdType="pmc">PMC8014194</ArticleId><ArticleId IdType="pubmed">33787826</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen JB, Cohen DL, Herman DS, Leppert JT, Byrd JB, Bhalla V. Testing for primary aldosteronism and mineralocorticoid receptor antagonist use among U.S. veterans: a retrospective cohort study. Ann Intern Med 2021; 174:289&#x2013;297.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7965294</ArticleId><ArticleId IdType="pubmed">33370170</ArticleId></ArticleIdList></Reference><Reference><Citation>Hundemer GL, Imsirovic H, Vaidya A, Yozamp N, Goupil R, Madore F, Agharazii M, Knoll G, Sood MM. Screening rates for primary aldosteronism among individuals with hypertension plus hypokalemia: a population-based retrospective cohort study. Hypertension 2022; 79:178&#x2013;186.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8664996</ArticleId><ArticleId IdType="pubmed">34657442</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu YY, King J, Kline GA, Padwal RS, Pasieka JL, Chen G, So B, Harvey A, Chin A, Leung AA. Outcomes of a specialized clinic on rates of investigation and treatment of primary aldosteronism. JAMA Surg 2021; 156:541&#x2013;549.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8014194</ArticleId><ArticleId IdType="pubmed">33787826</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossi GP. Primary aldosteronism: JACC state-of-the-art review. J Am Coll Cardiol 2019; 74:2799&#x2013;2811.</Citation><ArticleIdList><ArticleId IdType="pubmed">31779795</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaidya A, Underwood PC, Hopkins PN, Jeunemaitre X, Ferri C, Williams GH, Adler GK. Abnormal aldosterone physiology and cardiometabolic risk factors. Hypertension 2013; 61:886&#x2013;893.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3615445</ArticleId><ArticleId IdType="pubmed">23399714</ArticleId></ArticleIdList></Reference><Reference><Citation>Hung A, Ahmed S, Gupta A, Davis A, Kline GA, Leung AA, Ruzicka M, Hiremath S, Hundemer GL. Performance of the aldosterone to renin ratio as a screening test for primary aldosteronism. J Clin Endocrinol Metab 2021; 106:2423&#x2013;2435.</Citation><ArticleIdList><ArticleId IdType="pubmed">34008000</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossi GP, Ceolotto G, Rossitto G, Maiolino G, Cesari M, Seccia TM. Effects of mineralocorticoid and AT1 receptor antagonism on the aldosterone-renin ratio in primary aldosteronism-the EMIRA study. J Clin Endocrinol Metab 2020; 105:2060&#x2013;2067. doi:10.1210/clinem/dgaa080</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/clinem/dgaa080</ArticleId><ArticleId IdType="pubmed">32067030</ArticleId></ArticleIdList></Reference><Reference><Citation>Nanba AT, Wannachalee T, Shields JJ, Byrd JB, Rainey WE, Auchus RJ, Turcu AF. Adrenal vein sampling lateralization despite mineralocorticoid receptor antagonists exposure in primary aldosteronism. J Clin Endocrinol Metab 2019; 104:487&#x2013;492.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6316984</ArticleId><ArticleId IdType="pubmed">30239792</ArticleId></ArticleIdList></Reference><Reference><Citation>Funder JW, Carey RM, Mantero F, Murad MH, Reincke M, Shibata H, Stowasser M, Young WF. The management of primary aldosteronism: case detection, diagnosis, and treatment: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2016; 101:1889&#x2013;1916.</Citation><ArticleIdList><ArticleId IdType="pubmed">26934393</ArticleId></ArticleIdList></Reference><Reference><Citation>Pecori A, Buffolo F, Burrello J, Mengozzi G, Rumbolo F, Avataneo V, D&#x2019;Avolio A, Rabbia F, Bertello C, Veglio F, Mulatero P, Monticone S. Mineralocorticoid receptor antagonist effect on aldosterone to renin ratio in patients with primary aldosteronism. J Clin Endocrinol Metab 2021; 106:e3655&#x2013;e3664.</Citation><ArticleIdList><ArticleId IdType="pubmed">33942084</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo Z, Poglitsch M, McWhinney BC, Ungerer JPJ, Ahmed AH, Gordon RD, Wolley M, Stowasser M. Aldosterone LC-MS/MS assay-specific threshold values in screening and confirmatory testing for primary aldosteronism. J Clin Endocrinol Metab 2018; 103:3965&#x2013;3973.</Citation><ArticleIdList><ArticleId IdType="pubmed">30137438</ArticleId></ArticleIdList></Reference><Reference><Citation>Thuzar M, Young K, Ahmed AH, Ward G, Wolley M, Guo Z, Gordon RD, McWhinney BC, Ungerer JP, Stowasser M. Diagnosis of primary aldosteronism by seated saline suppression test - variability between immunoassay and HPLC-MS/MS. J Clin Endocrinol Metab 2019; 105:e477&#x2013;e483.</Citation><ArticleIdList><ArticleId IdType="pubmed">31676899</ArticleId></ArticleIdList></Reference><Reference><Citation>Eisenhofer G, Kurlbaum M, Peitzsch M, Constantinescu G, Remde H, Schulze M, Kaden D, M&#xfc;ller LM, Fuss CT, Kunz S, Ko&#x142;odziejczyk-Kruk S, Gruber S, Prejbisz A, Beuschlein F, Williams TA, Reincke M, Lenders JWM, Bidlingmaier M. The saline infusion test for primary aldosteronism: implications of immunoassay inaccuracy. J Clin Endocrinol Metab 2022; 6:1&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9016451</ArticleId><ArticleId IdType="pubmed">34963138</ArticleId></ArticleIdList></Reference><Reference><Citation>Baron S, Amar L, Faucon AL, Blanchard A, Baffalie L, Faucard C, Travers S, Pagny JY, Azizi M, Houillier P. Criteria for diagnosing primary aldosteronism on the basis of liquid chromatography-tandem mass spectrometry determinations of plasma aldosterone concentration. J Hypertens 2018; 36:1592&#x2013;1601.</Citation><ArticleIdList><ArticleId IdType="pubmed">29677048</ArticleId></ArticleIdList></Reference><Reference><Citation>Le Goff CM, Gonzalez-Antu&#xf1;a A, Peeters SD, Fabregat-Cabello N, Van Der Gugten JG, Vroonen L, Pottel H, Holmes DT, Cavalier E. Migration from RIA to LC-MS/MS for aldosterone determination: implications for clinical practice and determination of plasma and urine reference range intervals in a cohort of healthy Belgian subjects. Clin Mass Spectrom 2018; 9:7&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11322751</ArticleId><ArticleId IdType="pubmed">39193352</ArticleId></ArticleIdList></Reference><Reference><Citation>Fuss CT, Brohm K, Kurlbaum M, Hannemann A, Kendl S, Fassnacht M, Deutschbein T, Hahner S, Kroiss M. Confirmatory testing of primary aldosteronism with saline infusion test and LC-MS/MS. Eur J Endocrinol 2021; 184:167&#x2013;178.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7709890</ArticleId><ArticleId IdType="pubmed">33112272</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishikawa T, Satoh F, Takashi Y, Yanase T, Itoh H, Kurihara I, Shibata H, Oki Y, Naruse M, Sasamoto H, Kuwa K. Comparison and commutability study between standardized liquid chromatography-mass spectrometry/mass spectrometry (LC-MS/MS) and chemiluminescent enzyme immunoassay for aldosterone measurement in blood. Endocr J 2022; 69:EJ21-0278.</Citation><ArticleIdList><ArticleId IdType="pubmed">34305069</ArticleId></ArticleIdList></Reference><Reference><Citation>Ozeki Y, Tanimura Y, Nagai S, Nomura T, Kinoshita M, Shibuta K, Matsuda N, Miyamoto S, Yoshida Y, Okamoto M, Gotoh K, Masaki T, Kambara K, Shibata H. Development of a new chemiluminescent enzyme immunoassay using a two-step sandwich method for measuring aldosterone concentrations. Diagnostics 2021; 11. doi:10.3390/diagnostics11030433</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/diagnostics11030433</ArticleId><ArticleId IdType="pmc">PMC8001557</ArticleId><ArticleId IdType="pubmed">33806394</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin Y, Ma C, Yu S, Liu W, Wang D, You T, Cheng Q, Qiu L. Comparison of three different chemiluminescence assays and a rapid liquid chromatography tandem mass spectrometry method for measuring serum aldosterone. Clin Chem Lab Med 2020; 58:95&#x2013;102. doi:10.1515/cclm-2019-0706</Citation><ArticleIdList><ArticleId IdType="doi">10.1515/cclm-2019-0706</ArticleId><ArticleId IdType="pubmed">31655792</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown JM, Auchus RJ, Honzel B, Luther JM, Yozamp N, Vaidya A. Recalibrating interpretations of aldosterone assays across the physiologic range: immunoassay and liquid chromatography&#x2013;tandem mass spectrometry measurements under multiple controlled conditions. J Endocr Soc 2022; 6. doi:10.1210/jendso/bvac049</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/jendso/bvac049</ArticleId><ArticleId IdType="pmc">PMC9032635</ArticleId><ArticleId IdType="pubmed">35475027</ArticleId></ArticleIdList></Reference><Reference><Citation>Yozamp N, Hundemer GL, Moussa M, Underhill J, Fudim T, Sacks B, Vaidya A. Variability of aldosterone measurements during adrenal venous sampling for primary aldosteronism. Am J Hypertens 2021; 34:34&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7891268</ArticleId><ArticleId IdType="pubmed">33179734</ArticleId></ArticleIdList></Reference><Reference><Citation>Fries CM, Bae YJ, Rayes N, Sandner B, Isermann B, Stumvoll M, Fagotto V, Reincke M, Bidlingmaier M, Mandy V, Kratzsch J, Fenske WK. Prospective evaluation of aldosterone LC-MS/ MS-specific cutoffs for the saline infusion test. Eur J Endocrinol 2020; 183:191&#x2013;201.</Citation><ArticleIdList><ArticleId IdType="pubmed">32460235</ArticleId></ArticleIdList></Reference><Reference><Citation>Vieweg WVR, Veldhuis JD, Carey RM. Temporal pattern of renin and aldosterone secretion in men: effects of sodium balance. Am J Physiol Renal Physiol 1992; 262:F871&#x2013;F877.</Citation><ArticleIdList><ArticleId IdType="pubmed">1590429</ArticleId></ArticleIdList></Reference><Reference><Citation>Siragy HM, Vieweg WV, Pincus S, Veldhuis JD. Increased disorderliness and amplified basal and pulsatile aldosterone secretion in patients with primary aldosteronism. J Clin Endocrinol Metab 1995; 80:28&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pubmed">7829626</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanabe A, Naruse M, Takagi S, Tsuchiya K, Imaki T, Takano K. Variability in the renin/aldosterone profile under random and standardized sampling conditions in primary aldosteronism. J Clin Endocrinol Metab 2003; 88:2489&#x2013;2494.</Citation><ArticleIdList><ArticleId IdType="pubmed">12788844</ArticleId></ArticleIdList></Reference><Reference><Citation>Kline GA, Darras P, Leung AA, So B, Chin A, Holmes DT. Surprisingly low aldosterone levels in peripheral veins following intravenous sedation during adrenal vein sampling: implications for the concept of nonsuppressibility in primary aldosteronism. J Hypertens 2019; 37:596&#x2013;602.</Citation><ArticleIdList><ArticleId IdType="pubmed">30703073</ArticleId></ArticleIdList></Reference><Reference><Citation>Yozamp N, Hundemer GL, Moussa M, Underhill J, Fudim T, Sacks B, Vaidya A. Intraindividual variability of aldosterone concentrations in primary aldosteronism: implications for case detection. Hypertension 2021; 77:891&#x2013;899.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7878320</ArticleId><ArticleId IdType="pubmed">33280409</ArticleId></ArticleIdList></Reference><Reference><Citation>Tezuka Y, Ishii K, Zhao L, Yamazaki Y, Morimoto R, Sasano H, Udager AM, Satoh F, Turcu AF. ACTH stimulation maximizes the accuracy of peripheral steroid profiling in primary aldosteronism subtyping. J Clin Endocrinol Metab 2021; 106:e3969&#x2013;e3978.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8475211</ArticleId><ArticleId IdType="pubmed">34117870</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsiavos V, Markou A, Papanastasiou L, Kounadi T, Androulakis II, Voulgaris N, Zachaki A, Kassi E, Kaltsas G, Chrousos GP, Piaditis GP. A new highly sensitive and specific overnight combined screening and diagnostic test for primary aldosteronism. Eur J Endocrinol 2016; 175:21&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="pubmed">27072145</ArticleId></ArticleIdList></Reference><Reference><Citation>Teo AE, Garg S, Shaikh LH, Zhou J, Karet Frankl FE, Gurnell M, Happerfield L, Marker A, Bienz M, Azizan EA, Brown MJ. Pregnancy, primary aldosteronism, and adrenal CTNNB1 mutations. N Engl J Med 2015; 373:1429&#x2013;1436.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4612399</ArticleId><ArticleId IdType="pubmed">26397949</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang J, Libianto R, Lau KK, Doery JCG, Wan KL, Chee NYN, Shen J, Fuller PJ, Chong W. Impact of intraprocedural sedation on adrenal vein sampling without corticotropin stimulation. Radiology 2022:212627. doi:10.1148/radiol.212627</Citation><ArticleIdList><ArticleId IdType="doi">10.1148/radiol.212627</ArticleId><ArticleId IdType="pubmed">35608441</ArticleId></ArticleIdList></Reference><Reference><Citation>Stowasser M, Ahmed AH, Cowley D, Wolley M, Guo Z, McWhinney BC, Ungerer JP, Gordon RD. Comparison of seated with recumbent saline suppression testing for the diagnosis of primary aldosteronism. J Clin Endocrinol Metab 2018; 103:4113&#x2013;4124.</Citation><ArticleIdList><ArticleId IdType="pubmed">30239841</ArticleId></ArticleIdList></Reference><Reference><Citation>Umakoshi H, Sakamoto R, Matsuda Y, Yokomoto-Umakoshi M, Nagata H, Fukumoto T, Ogata M, Ogawa Y. Role of Aldosterone and potassium levels in sparing confirmatory tests in primary aldosteronism. J Clin Endocrinol Metab 2020; 105:1284&#x2013;1289.</Citation><ArticleIdList><ArticleId IdType="pubmed">31665338</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang K, Hu J, Yang J, Song Y, Fuller PJ, Hashimura H, He W, Feng Z, Cheng Q, Du Z, Wang Z, Ma L, Yang S, Li Q. Development and validation of criteria for sparing confirmatory tests in diagnosing primary aldosteronism. J Clin Endocrinol Metab 2020; 105:e2449&#x2013;e2456.</Citation><ArticleIdList><ArticleId IdType="pubmed">32449927</ArticleId></ArticleIdList></Reference><Reference><Citation>Stowasser M, Ahmed AH, Pimenta E, Taylor PJ, Gordon RD. Factors affecting the aldosterone/renin ratio. Horm Metab Res 2012; 44:170&#x2013;176.</Citation><ArticleIdList><ArticleId IdType="pubmed">22147655</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams B, Macdonald TM, Morant S, Webb DJ, Sever P, McInnes G, Ford I, Cruickshank JK, Caulfield MJ, Salsbury J, Mackenzie I, Padmanabhan S, Brown MJ. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet 2015; 386:2059&#x2013;2068.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4655321</ArticleId><ArticleId IdType="pubmed">26414968</ArticleId></ArticleIdList></Reference><Reference><Citation>Maeoka Y, Su XT, Wang WH, Duan XP, Sharma A, Li N, Staub O, McCormick JA, Ellison DH. Mineralocorticoid receptor antagonists cause natriuresis in the absence of aldosterone. Hypertension 2022; 79:1423&#x2013;1434. doi:10.1161/HYPERTENSIONAHA.122.19159</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/HYPERTENSIONAHA.122.19159</ArticleId><ArticleId IdType="pmc">PMC9177775</ArticleId><ArticleId IdType="pubmed">35506380</ArticleId></ArticleIdList></Reference><Reference><Citation>Fukumoto T, Umakoshi H, Ogata M, Yokomoto-Umakoshi M, Matsuda Y, Motoya M, Nagata H, Nakano Y, Iwahashi N, Kaneko H, Wada N, Miyazawa T, Sakamoto R, Ogawa Y. Significance of discordant results between confirmatory tests in diagnosis of primary aldosteronism. J Clin Endocrinol Metab 2021; 106:e866&#x2013;e874.</Citation><ArticleIdList><ArticleId IdType="pubmed">33165595</ArticleId></ArticleIdList></Reference><Reference><Citation>Leung AA, Symonds CJ, Hundemer GL, Ronksley PE, Lorenzetti DL, Pasieka JL, Harvey A, Kline GA. Performance of confirmatory tests for diagnosing primary aldosteronism: a systematic review and meta-analysis. Hypertension 2022; 79:1835&#x2013;1844. doi:10.1161/HYPERTENSIONAHA.122.19377</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/HYPERTENSIONAHA.122.19377</ArticleId><ArticleId IdType="pmc">PMC9278709</ArticleId><ArticleId IdType="pubmed">35652330</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaidya A, Carey RM. Evolution of the primary aldosteronism syndrome: updating the approach. J Clin Endocrinol Metab 2020; 105:3771&#x2013;3783.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7899564</ArticleId><ArticleId IdType="pubmed">32865201</ArticleId></ArticleIdList></Reference><Reference><Citation>Funder JW. Primary aldosteronism: three strikes and out. Hypertension 2021; 77:900&#x2013;903.</Citation><ArticleIdList><ArticleId IdType="pubmed">33566688</ArticleId></ArticleIdList></Reference><Reference><Citation>Helber A, Wambach G, Hummerich W, Bonner G, Meurer KA, Kaufmann W. Evidence for a subgroup of essential hypertensives with non-suppressible excretion of aldosterone during sodium loading. Klin Wochenschr 1980; 58:439&#x2013;447.</Citation><ArticleIdList><ArticleId IdType="pubmed">6993778</ArticleId></ArticleIdList></Reference><Reference><Citation>Peng KY, Liao HW, Chan CK, Lin WC, Yang SY, Tsai YC, Huang KH, Lin YH, Chueh JS, Wu VC. Presence of subclinical hypercortisolism in clinical aldosterone-producing adenomas predicts lower clinical success. Hypertension 2020; 76:1537&#x2013;1544.</Citation><ArticleIdList><ArticleId IdType="pubmed">32921192</ArticleId></ArticleIdList></Reference><Reference><Citation>Gerards J, Heinrich DA, Adolf C, Meisinger C, Rathmann W, Sturm L, Nirschl N, Bidlingmaier M, Beuschlein F, Thorand B, Peters A, Reincke M, Roden M, Quinkler M. Impaired glucose metabolism in primary aldosteronism is associated with cortisol cosecretion. J Clin Endocrinol Metab 2019; 104:3192&#x2013;3202.</Citation><ArticleIdList><ArticleId IdType="pubmed">30865224</ArticleId></ArticleIdList></Reference><Reference><Citation>Akehi Y, Yanase T, Motonaga R, Umakoshi H, Tsuiki M, Takeda Y, Yoneda T, Kurihara I, Itoh H, Katabami T, Ichijo T, Wada N, Shibayama Y, Yoshimoto T, Ashida K, Ogawa Y, Kawashima J, Sone M, Inagaki N, Takahashi K, Fujita M, Watanabe M, Matsuda Y, Kobayashi H, Shibata H, Kamemura K, Otsuki M, Fujii Y, Yamamoto K, Ogo A, Okamura S, Miyauchi S, Fukuoka T, Izawa S, Hashimoto S, Yamada M, Yoshikawa Y, Kai T, Suzuki T, Kawamura T, Naruse M. High prevalence of diabetes in patients with primary aldosteronism (PA) associated with subclinical hypercortisolism and prediabetes more prevalent in bilateral than unilateral PA: a large, multicenter cohort study in Japan. Diabetes Care 2019; 42:938&#x2013;945.</Citation><ArticleIdList><ArticleId IdType="pubmed">31010944</ArticleId></ArticleIdList></Reference><Reference><Citation>Gendreitzig P, K&#xfc;nzel HE, Adolf C, Handgriff L, M&#xfc;ller L, Holler F, Sturm L, Heinrich DA, Reincke M, Quinkler M. Autonomous cortisol secretion influences psychopathological symptoms in patients with primary aldosteronism. J Clin Endocrinol Metab 2021; 106:e2423&#x2013;e2433.</Citation><ArticleIdList><ArticleId IdType="pubmed">33596311</ArticleId></ArticleIdList></Reference><Reference><Citation>Katabami T, Matsuba R, Kobayashi H, Nakagawa T, Kurihara I, Ichijo T, Tsuiki M, Wada N, Ogawa Y, Sone M, Inagaki N, Yoshimoto T, Takahashi K, Yamamoto K, Izawa S, Kakutani M, Tanabe A, Naruse M. Primary aldosteronism with mild autonomous cortisol secretion increases renal complication risk. Eur J Endocrinol 2022; 186:645&#x2013;655.</Citation><ArticleIdList><ArticleId IdType="pubmed">35380982</ArticleId></ArticleIdList></Reference><Reference><Citation>Heinrich DA, Adolf C, Holler F, Lechner B, Schneider H, Riester A, Nirschl N, Sturm L, Wang X, Ladurner R, Seidensticker M, Bidlingmaier M, Beuschlein F, Reincke M. Adrenal insufficiency after unilateral adrenalectomy in primary aldosteronism: long-term outcome and clinical impact. J Clin Endocrinol Metab 2019; 104:5658&#x2013;5664.</Citation><ArticleIdList><ArticleId IdType="pubmed">31225874</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Toole SM, Sze WC, Chung TT, Akker SA, Druce MR, Waterhouse M, Pitkin S, Dawnay A, Sahdev A, Matson M, Parvanta L, Drake WM. Low-grade cortisol cosecretion has limited impact on ACTH-stimulated AVS parameters in primary aldosteronism. J Clin Endocrinol Metab 2020; 105:e3776&#x2013;e3784. doi:10.1210/clinem/dgaa519</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/clinem/dgaa519</ArticleId><ArticleId IdType="pubmed">32785656</ArticleId></ArticleIdList></Reference><Reference><Citation>Bancos I, Prete A. Approach to the patient with adrenal incidentaloma. J Clin Endocrinol Metab 2021; 106:3331&#x2013;3353.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8530736</ArticleId><ArticleId IdType="pubmed">34260734</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaidya A, Hamrahian A, Bancos I, Fleseriu M, Ghayee HK. The evaluation of incidentally discovered adrenal masses. Endocr Pract 2019; 25:178&#x2013;192.</Citation><ArticleIdList><ArticleId IdType="pubmed">30817193</ArticleId></ArticleIdList></Reference><Reference><Citation>Fujimoto K, Honjo S, Tatsuoka H, Hamamoto Y, Kawasaki Y, Matsuoka A, Ikeda H, Wada Y, Sasano H, Koshiyama H. Primary aldosteronism associated with subclinical Cushing syndrome. J Endocrinol Invest 2013; 36:564&#x2013;567.</Citation><ArticleIdList><ArticleId IdType="pubmed">23385627</ArticleId></ArticleIdList></Reference><Reference><Citation>Fallo F, Bertello C, Tizzani D, Fassina A, Boulkroun S, Sonino N, Monticone S, Viola A, Veglio F, Mulatero P. Concurrent primary aldosteronism and subclinical cortisol hypersecretion: a prospective study. J Hypertens 2011; 29:1773&#x2013;1777.</Citation><ArticleIdList><ArticleId IdType="pubmed">21720261</ArticleId></ArticleIdList></Reference><Reference><Citation>Hiraishi K, Yoshimoto T, Tsuchiya K, Minami I, Doi M, Izumiyama H, Sasano H, Hirata Y. Clinicopathological features of primary aldosteronism associated with subclinical Cushing&#x2019;s syndrome. Endocr J 2011; 58:543&#x2013;551.</Citation><ArticleIdList><ArticleId IdType="pubmed">21521926</ArticleId></ArticleIdList></Reference><Reference><Citation>Honda K, Sone M, Tamura N, Sonoyama T, Taura D, Kojima K, Fukuda Y, Tanaka S, Yasuno S, Fujii T, Kinoshita H, Ariyasu H, Kanamoto N, Miura M, Yasoda A, Arai H, Ueshima K, Nakao K. Adrenal reserve function after unilateral adrenalectomy in patients with primary aldosteronism. J Hypertens 2013; 31:2010&#x2013;2017.</Citation><ArticleIdList><ArticleId IdType="pubmed">23846863</ArticleId></ArticleIdList></Reference><Reference><Citation>Adolf C, Kohler A, Franke A, Lang K, Riester A, Low A, Heinrich DA, Bidlingmaier M, Treitl M, Ladurner R, Beuschlein F, Arlt W, Reincke M. Cortisol excess in patients with primary aldosteronism impacts left ventricular hypertrophy. J Clin Endocrinol Metab 2018; 103:4543&#x2013;4552.</Citation><ArticleIdList><ArticleId IdType="pubmed">30113683</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsai CH, Liao CW, Wu XM, Chen ZW, Pan CT, Chang YY, Lee BC, Shun CT, Wen WF, Chou CH, Wu VC, Hung CS, Lin YH. Autonomous cortisol secretion is associated with worse arterial stiffness and vascular fibrosis in primary aldosteronism - a cross-sectional study with follow-up data. Eur J Endocrinol 2022; 187:187&#x2013;208. doi:10.1530/EJE-21-1157</Citation><ArticleIdList><ArticleId IdType="doi">10.1530/EJE-21-1157</ArticleId><ArticleId IdType="pubmed">35551115</ArticleId></ArticleIdList></Reference><Reference><Citation>DeLozier OM, Dream SY, Findling JW, Carroll TB, Evans DB, Wang TS. Selective glucocorticoid replacement following unilateral adrenalectomy for hypercortisolism and primary aldosteronism. J Clin Endocrinol Metab 2022; 107:e538&#x2013;e547.</Citation><ArticleIdList><ArticleId IdType="pubmed">34558612</ArticleId></ArticleIdList></Reference><Reference><Citation>Parksook WW, Yozamp N, Hundemer GL, Moussa M, Underhill J, Fudim T, Sacks B, Vaidya A. Morphologically normal-appearing adrenal glands as a prevalent source of aldosterone production in primary aldosteronism. Am J Hypertens 2022; 35:561&#x2013;571. doi:10.1093/ajh/hpab189</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ajh/hpab189</ArticleId><ArticleId IdType="pmc">PMC9890245</ArticleId><ArticleId IdType="pubmed">34883509</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossi GP, Barisa M, Allolio B, Auchus RJ, Amar L, Cohen D, Degenhart C, Deinum J, Fischer E, Gordon R, Kickuth R, Kline G, Lacroix A, Magill S, Miotto D, Naruse M, Nishikawa T, Omura M, Pimenta E, Plouin PF, Quinkler M, Reincke M, Rossi E, Rump LC, Satoh F, Schultze Kool L, Seccia TM, Stowasser M, Tanabe A, Trerotola S, Vonend O, Widimsky J Jr, Wu KD, Wu VC, Pessina AC. The Adrenal Vein Sampling International Study (AVIS) for identifying the major subtypes of primary aldosteronism. J Clin Endocrinol Metab 2012; 97:1606&#x2013;1614.</Citation><ArticleIdList><ArticleId IdType="pubmed">22399502</ArticleId></ArticleIdList></Reference><Reference><Citation>Kempers MJ, Lenders JW, van Outheusden L, van der Wilt GJ, Schultze Kool LJ, Hermus AR, Deinum J. Systematic review: diagnostic procedures to differentiate unilateral from bilateral adrenal abnormality in primary aldosteronism. Ann Intern Med 2009; 151:329&#x2013;337.</Citation><ArticleIdList><ArticleId IdType="pubmed">19721021</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Y, Wang D, Jiang L, Ran F, Chen S, Zhou P, Wang P. Diagnostic accuracy of adrenal imaging for subtype diagnosis in primary aldosteronism: systematic review and meta-analysis. BMJ Open 2020; 10:e038489.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7780716</ArticleId><ArticleId IdType="pubmed">33384386</ArticleId></ArticleIdList></Reference><Reference><Citation>Umakoshi H, Tsuiki M, Takeda Y, Kurihara I, Itoh H, Katabami T, Ichijo T, Wada N, Yoshimoto T, Ogawa Y, Kawashima J, Sone M, Inagaki N, Takahashi K, Watanabe M, Matsuda Y, Kobayashi H, Shibata H, Kamemura K, Otsuki M, Fujii Y, Yamamto K, Ogo A, Yanase T, Suzuki T, Naruse M. Significance of computed tomography and serum potassium in predicting subtype diagnosis of primary aldosteronism. J Clin Endocrinol Metab 2018; 103:900&#x2013;908.</Citation><ArticleIdList><ArticleId IdType="pubmed">29092077</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu F, Gao Z, Wang G, Gao Y, Guo Y, Guo Y, Zhou Z. Prevalence, subtype classification, and outcomes of treatment of primary aldosteronism: a prospective study in China. Endocr Pract 2021; 27:478&#x2013;483.</Citation><ArticleIdList><ArticleId IdType="pubmed">33853742</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams TA, Burrello J, Sechi LA, Fardella CE, Matrozova J, Adolf C, Baudrand R, Bernardi S, Beuschlein F, Catena C, Doumas M, Fallo F, Giacchetti G, Heinrich DA, Saint-Hilary G, Jansen PM, Januszewicz A, Kocjan T, Nishikawa T, Quinkler M, Satoh F, Umakoshi H, Widimsk&#xfd; J Jr, Hahner S, Douma S, Stowasser M, Mulatero P, Reincke M. Computed tomography and adrenal venous sampling in the diagnosis of unilateral primary aldosteronism. Hypertension 2018; 72:641&#x2013;649.</Citation><ArticleIdList><ArticleId IdType="pubmed">29987100</ArticleId></ArticleIdList></Reference><Reference><Citation>Sam D, Kline GA, So B, Leung AA. Discordance between imaging and adrenal vein sampling in primary aldosteronism irrespective of interpretation criteria. J Clin Endocrinol Metab 2019; 104:1900&#x2013;1906.</Citation><ArticleIdList><ArticleId IdType="pubmed">30590677</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossi GP, Crim&#xec; F, Rossitto G, Amar L, Azizi M, Riester A, Reincke M, Degenhart C, Widimsky J, Naruse M, Deinum J, Schultze Kool L, Kocjan T, Negro A, Rossi E, Kline G, Tanabe A, Satoh F, Christian Rump L, Vonend O, Willenberg HS, Fuller PJ, Yang J, Chee NYN, Magill SB, Shafigullina Z, Quinkler M, Oliveras A, Cent Wu V, Kratka Z, Barbiero G, Seccia TM, Battistel M. Identification of surgically curable primary aldosteronism by imaging in a large, multiethnic International study. J Clin Endocrinol Metab 2021; 106:e4340&#x2013;e4349.</Citation><ArticleIdList><ArticleId IdType="pubmed">34212188</ArticleId></ArticleIdList></Reference><Reference><Citation>Naruse M, Katabami T, Shibata H, Sone M, Takahashi K, Tanabe A, Izawa S, Ichijo T, Otsuki M, Omura M, Ogawa Y, Oki Y, Kurihara I, Kobayashi H, Sakamoto R, Satoh F, Takeda Y, Tanaka T, Tamura K, Tsuiki M, Hashimoto S, Hasegawa T, Yoshimoto T, Yoneda T, Yamamoto K, Rakugi H, Wada N, Saiki A, Ohno Y, Haze T. Japan Endocrine Society clinical practice guideline for the diagnosis and management of primary aldosteronism 2021. Endocr J 2022; 69:327&#x2013;359. doi:10.1507/endocrj.EJ21-0508</Citation><ArticleIdList><ArticleId IdType="doi">10.1507/endocrj.EJ21-0508</ArticleId><ArticleId IdType="pubmed">35418526</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu VC, Hu YH, Er LK, Yen RF, Chang CH, Chang YL, Lu CC, Chang CC, Lin JH, Lin YH, Wang TD, Wang CY, Tu ST, Jeff Chueh SC, Chang CC, Tseng FY, Wu KD. Case detection and diagnosis of primary aldosteronism&#x2014;the consensus of Taiwan Society of Aldosteronism. J Formos Med Assoc 2017; 116:993&#x2013;1005.</Citation><ArticleIdList><ArticleId IdType="pubmed">28735660</ArticleId></ArticleIdList></Reference><Reference><Citation>Gkaniatsa E, Sakinis A, Palm&#xe9;r M, Muth A, Trimpou P, Ragnarsson O. Adrenal venous sampling in young patients with primary aldosteronism. extravagance or irreplaceable? J Clin Endocrinol Metab 2021; 106:e2087&#x2013;e2095.</Citation><ArticleIdList><ArticleId IdType="pubmed">33507307</ArticleId></ArticleIdList></Reference><Reference><Citation>Umakoshi H, Ogasawara T, Takeda Y, Kurihara I, Itoh H, Katabami T, Ichijo T, Wada N, Shibayama Y, Yoshimoto T, Ogawa Y, Kawashima J, Sone M, Inagaki N, Takahashi K, Watanabe M, Matsuda Y, Kobayashi H, Shibata H, Kamemura K, Otsuki M, Fujii Y, Yamamto K, Ogo A, Yanase T, Okamura S, Miyauchi S, Suzuki T, Tsuiki M, Naruse M. Accuracy of adrenal computed tomography in predicting the unilateral subtype in young patients with hypokalaemia and elevation of aldosterone in primary aldosteronism. Clin Endocrinol 2018; 88:645&#x2013;651.</Citation><ArticleIdList><ArticleId IdType="pubmed">29464741</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossi GP, Crim&#xec; F, Rossitto G, Amar L, Azizi M, Riester A, Reincke M, Degenhart C, Widimsky J, Naruse M, Deinum J, Kool LS, Kocjan T, Negro A, Rossi E, Kline G, Tanabe A, Satoh F, Rump LC, Vonend O, Willenberg HS, Fuller PJ, Yang J, Chee NYN, Magill SB, Shafigullina Z, Quinkler M, Oliveras A, Wu VC, Kratka Z, Barbiero G, Battistel M, Seccia TM. Feasibility of imaging-guided adrenalectomy in young patients with primary aldosteronism. Hypertension 2022; 79:187&#x2013;195.</Citation><ArticleIdList><ArticleId IdType="pubmed">34878892</ArticleId></ArticleIdList></Reference><Reference><Citation>Kline GA, Leung AA, Sam D, Chin A, So B. Repeat adrenal vein sampling in aldosteronism: reproducibility and interpretation of persistently discordant results. J Clin Endocrinol Metab 2021; 106:e1170&#x2013;e1178.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7947749</ArticleId><ArticleId IdType="pubmed">33320942</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossitto G, Battistel M, Barbiero G, Bisogni V, Maiolino G, Diego M, Seccia TM, Rossi GP. The subtyping of primary aldosteronism by adrenal vein sampling: sequential blood sampling causes factitious lateralization. J Hypertens 2018; 36:335&#x2013;343.</Citation><ArticleIdList><ArticleId IdType="pubmed">28957852</ArticleId></ArticleIdList></Reference><Reference><Citation>Laurent I, Ast&#xe8;re M, Zheng F, Chen X, Yang J, Cheng Q, Li Q. Adrenal venous sampling with or without adrenocorticotropic hormone stimulation: a meta-analysis. J Clin Endocrinol Metab 2018; 104:1060&#x2013;1068. doi:10.1210/jc.2018-01324</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/jc.2018-01324</ArticleId><ArticleId IdType="pubmed">30403797</ArticleId></ArticleIdList></Reference><Reference><Citation>Takeda Y, Umakoshi H, Takeda Y, Yoneda T, Kurihara I, Katabami T, Ichijo T, Wada N, Yoshimoto T, Ogawa Y, Kawashima J, Sone M, Takahashi K, Watanabe M, Matsuda Y, Kobayashi H, Shibata H, Kamemura K, Otsuki M, Fujii Y, Yamamto K, Ogo A, Yanase T, Suzuki T, Naruse M. Impact of adrenocorticotropic hormone stimulation during adrenal venous sampling on outcomes of primary aldosteronism. J Hypertens 2019; 37:1077&#x2013;1082.</Citation><ArticleIdList><ArticleId IdType="pubmed">30601318</ArticleId></ArticleIdList></Reference><Reference><Citation>Yozamp N, Hundemer GL, Moussa M, Underhill J, Fudim T, Sacks B, Vaidya A. Adrenocorticotropic hormone-stimulated adrenal venous sampling underestimates surgically curable primary aldosteronism: a retrospective cohort study and review of contemporary studies. Hypertension 2021; 78:94&#x2013;103.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8192472</ArticleId><ArticleId IdType="pubmed">33993726</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossitto G, Amar L, Azizi M, Riester A, Reincke M, Degenhart C, Widimsky J, Naruse M, Deinum J, Schultzekool L, Kocjan T, Negro A, Rossi E, Kline G, Tanabe A, Satoh F, Rump LC, Vonend O, Willenberg HS, Fuller P, Yang J, Nian Chee NY, Magill SB, Shafigullina Z, Quinkler M, Oliveras A, Chang CC, Wu VC, Somloova Z, Maiolino G, Barbiero G, Battistel M, Lenzini L, Quaia E, Pessina AC, Rossi GP. Subtyping of primary aldosteronism in the AVIS-2 study: assessment of selectivity and lateralization. J Clin Endocrinol Metab 2020; 105:2042&#x2013;2052. doi:10.1210/clinem/dgz017</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/clinem/dgz017</ArticleId><ArticleId IdType="pubmed">31536622</ArticleId></ArticleIdList></Reference><Reference><Citation>Hafezi-Nejad N, Gullotti DM, Bailey CR, Lessne ML, Holly BP. Does intraprocedural CT improve the success rate of adrenal venous sampling? A systematic review and meta-analysis of data from 809 patients. Cardiovasc Intervent Radiol 2022; 45:29&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">34518912</ArticleId></ArticleIdList></Reference><Reference><Citation>Busser WM, Arntz MJ, Jenniskens SF, Deinum J, Hoogeveen YL, de Lange F, Schultze Kool LJ. Image registration of cone-beam computer tomography and preprocedural computer tomography aids in localization of adrenal veins and decreasing radiation dose in adrenal vein sampling. Cardiovasc Intervent Radiol 2015; 38:993&#x2013;997.</Citation><ArticleIdList><ArticleId IdType="pubmed">25238715</ArticleId></ArticleIdList></Reference><Reference><Citation>Reardon MA, Angle JF, Abi-Jaoudeh N, Bruns DE, Haverstick DM, Matsumoto AH, Carey RM. Intraprocedural cortisol levels in the evaluation of proper catheter placement in adrenal venous sampling. J Vasc Interv Radiol 2011; 22:1575&#x2013;1580.</Citation><ArticleIdList><ArticleId IdType="pubmed">21700477</ArticleId></ArticleIdList></Reference><Reference><Citation>Augustin AM, Dalla Torre G, Fuss CT, Fassnacht M, Bley TA, Kickuth R. Reduction of radiation exposure in adrenal vein sampling: impact of the rapid cortisol assay [Reduktion der Strahlenbelastung bei der selektiven Nebennierenvenenblutentnahme: Einfluss des Kortison-Schnelltests]. Rofo 2021; 193:1392&#x2013;1402.</Citation><ArticleIdList><ArticleId IdType="pubmed">34384111</ArticleId></ArticleIdList></Reference><Reference><Citation>Kline G, Leung A, So B, Chin A, Harvey A, Pasieka JL. Application of strict criteria in adrenal venous sampling increases the proportion of missed patients with unilateral disease who benefit from surgery for primary aldosteronism. J Hypertens 2018; 36:1407&#x2013;1413.</Citation><ArticleIdList><ArticleId IdType="pubmed">29465715</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossi GP, Auchus RJ, Brown M, Lenders JW, Naruse M, Plouin PF, Satoh F, Young WF Jr. An expert consensus statement on use of adrenal vein sampling for the subtyping of primary aldosteronism. Hypertension 2014; 63:151&#x2013;160.</Citation><ArticleIdList><ArticleId IdType="pubmed">24218436</ArticleId></ArticleIdList></Reference><Reference><Citation>Kline GA, So B, Campbell DJT, Chin A, Harvey A, Venos E, Pasieka J, Leung AA. Apparent failed and discordant adrenal vein sampling: a potential confounding role of cortisol cosecretion? Clin Endocrinol 2022; 96:123&#x2013;131.</Citation><ArticleIdList><ArticleId IdType="pubmed">34160833</ArticleId></ArticleIdList></Reference><Reference><Citation>Dekkers T, Prejbisz A, Kool LJS, Groenewoud H, Velema M, Spiering W, Ko&#x142;odziejczyk-Kruk S, Arntz M, K&#x105;dziela J, Langenhuijsen JF, Kerstens MN, van den Meiracker AH, van den Born BJ, Sweep F, Hermus A, Januszewicz A, Ligthart-Naber AF, Makai P, van der Wilt GJ, Lenders JWM, Deinum J.. Adrenal vein sampling versus CT scan to determine treatment in primary aldosteronism: an outcome-based randomised diagnostic trial. Lancet Diabetes Endocrinol 2016; 4:739&#x2013;746.</Citation><ArticleIdList><ArticleId IdType="pubmed">27325147</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossi GP, Funder JW. Adrenal venous sampling versus computed tomographic scan to determine treatment in primary aldosteronism (The SPARTACUS Trial): a critique. Hypertension 2017; 69:396&#x2013;397.</Citation><ArticleIdList><ArticleId IdType="pubmed">28137983</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossi GP, Rossitto G, Amar L, Azizi M, Riester A, Reincke M, Degenhart C, Widimsky J Jr, Naruse M, Deinum J, Schultze Kool L, Kocjan T, Negro A, Rossi E, Kline G, Tanabe A, Satoh F, Christian Rump L, Vonend O, Willenberg HS, Fuller PJ, Yang J, Chee NYN, Magill SB, Shafigullina Z, Quinkler M, Oliveras A, Dun Wu K, Wu VC, Kratka Z, Barbiero G, Battistel M, Chang CC, Vanderriele PE, Pessina AC. Clinical outcomes of 1625 patients with primary aldosteronism subtyped with adrenal vein sampling. Hypertension 2019; 74:800&#x2013;808.</Citation><ArticleIdList><ArticleId IdType="pubmed">31476901</ArticleId></ArticleIdList></Reference><Reference><Citation>Perez-Rivas LG, Williams TA, Reincke M. Inherited forms of primary hyperaldosteronism: new genes, new phenotypes and proposition of a new classification. Exp Clin Endocrinol Diabetes 2019; 127:93&#x2013;99.</Citation><ArticleIdList><ArticleId IdType="pubmed">30199917</ArticleId></ArticleIdList></Reference><Reference><Citation>Duncan JL III, Fuhrman GM, Bolton JS, Bowen JD, Richardson WS. Laparoscopic adrenalectomy is superior to an open approach to treat primary hyperaldosteronism. Am Surg 2000; 66:932&#x2013;935; discussion 935&#x2013;936.</Citation><ArticleIdList><ArticleId IdType="pubmed">11261619</ArticleId></ArticleIdList></Reference><Reference><Citation>Meria P, Kempf BF, Hermieu JF, Plouin PF, Duclos JM. Laparoscopic management of primary hyperaldosteronism: clinical experience with 212 cases. J Urol 2003; 169:32&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pubmed">12478096</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossi H, Kim A, Prinz RA. Primary hyperaldosteronism in the era of laparoscopic adrenalectomy. Am Surg 2002; 68:253&#x2013;256; discussion 256&#x2013;357.</Citation><ArticleIdList><ArticleId IdType="pubmed">11893103</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacobsen NE, Campbell JB, Hobart MG. Laparoscopic versus open adrenalectomy for surgical adrenal disease. Can J Urol 2003; 10:1995&#x2013;1999.</Citation><ArticleIdList><ArticleId IdType="pubmed">14633327</ArticleId></ArticleIdList></Reference><Reference><Citation>Desrochers MJ, St-Jean M, El Ghorayeb N, Bourdeau I, So B, Therasse E, Kline G, Lacroix A. Basal contralateral aldosterone suppression is rare in lateralized primary aldosteronism. Eur J Endocrinol 2020; 183:399&#x2013;409.</Citation><ArticleIdList><ArticleId IdType="pubmed">32698132</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams TA, Lenders JWM, Mulatero P, Burrello J, Rottenkolber M, Adolf C, Satoh F, Amar L, Quinkler M, Deinum J, Beuschlein F, Kitamoto KK, Pham U, Morimoto R, Umakoshi H, Prejbisz A, Kocjan T, Naruse M, Stowasser M, Nishikawa T, Young WF Jr, Gomez-Sanchez CE, Funder JW, Reincke M; Primary Aldosteronism Surgery Outcome (PASO) investigators. Outcomes after adrenalectomy for unilateral primary aldosteronism: an international consensus on outcome measures and analysis of remission rates in an international cohort. Lancet Diabetes Endocrinol 2017; 5:689&#x2013;699.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5572673</ArticleId><ArticleId IdType="pubmed">28576687</ArticleId></ArticleIdList></Reference><Reference><Citation>Katabami T, Fukuda H, Tsukiyama H, Tanaka Y, Takeda Y, Kurihara I, Ito H, Tsuiki M, Ichijo T, Wada N, Shibayama Y, Yoshimoto T, Ogawa Y, Kawashima J, Sone M, Inagaki N, Takahashi K, Fujita M, Watanabe M, Matsuda Y, Kobayashi H, Shibata H, Kamemura K, Otsuki M, Fujii Y, Yamamoto K, Ogo A, Yanase T, Suzuki T, Naruse M; JPAS/JRAS Study Group. Clinical and biochemical outcomes after adrenalectomy and medical treatment in patients with unilateral primary aldosteronism. J Hypertens 2019; 37:1513&#x2013;1520.</Citation><ArticleIdList><ArticleId IdType="pubmed">31145370</ArticleId></ArticleIdList></Reference><Reference><Citation>Swearingen AJ, Kahramangil B, Monteiro R, Krishnamurthy V, Jin J, Shin J, Siperstein A, Berber E. Analysis of postoperative biochemical values and clinical outcomes after adrenalectomy for primary aldosteronism. Surgery 2018; 163:807&#x2013;810.</Citation><ArticleIdList><ArticleId IdType="pubmed">29249599</ArticleId></ArticleIdList></Reference><Reference><Citation>Sellgren F, Koman A, Nordenstrom E, Hellman P, Hennings J, Muth A. Outcomes after surgery for unilateral dominant primary aldosteronism in Sweden. World J Surg 2020; 44:561&#x2013;569.</Citation><ArticleIdList><ArticleId IdType="pubmed">31720794</ArticleId></ArticleIdList></Reference><Reference><Citation>Picado O, Whitfield BW, Khan ZF, Jeraq M, Farra JC, Lew JI. Long-term outcome success after operative treatment for primary aldosteronism. Surgery 2021; 169:528&#x2013;532.</Citation><ArticleIdList><ArticleId IdType="pubmed">32948336</ArticleId></ArticleIdList></Reference><Reference><Citation>Takamatsu K, Takeda T, Hattori S, Tanaka N, Morita S, Matsumoto K, Kosaka T, Mizuno R, Shinojima T, Kikuchi E, Asanuma H, Kurihara I, Itoh H, Oya M. Appropriate timing for a biochemical evaluation after adrenalectomy for unilateral aldosterone-producing adenoma. Clin Endocrinol 2020; 92:503&#x2013;508.</Citation><ArticleIdList><ArticleId IdType="pubmed">32068902</ArticleId></ArticleIdList></Reference><Reference><Citation>Rutherford JC, Taylor WL, Stowasser M, Gordon RD. Success of surgery for primary aldosteronism judged by residual autonomous aldosterone production. World J Surg 1998; 22:1243&#x2013;1245.</Citation><ArticleIdList><ArticleId IdType="pubmed">9841751</ArticleId></ArticleIdList></Reference><Reference><Citation>Proye CA, Mulliez EA, Carnaille BM, Lecomte-Houcke M, Decoulx M, Wemeau JL, Lefebvre J, Racadot A, Ernst O, Huglo D, Carre A. Essential hypertension: first reason for persistent hypertension after unilateral adrenalectomy for primary aldosteronism? Surgery 1998; 124:1128&#x2013;1133.</Citation><ArticleIdList><ArticleId IdType="pubmed">9854594</ArticleId></ArticleIdList></Reference><Reference><Citation>Sukor N, Kogovsek C, Gordon RD, Robson D, Stowasser M. Improved quality of life, blood pressure, and biochemical status following laparoscopic adrenalectomy for unilateral primary aldosteronism. J Clin Endocrinol Metab 2010; 95:1360&#x2013;1364.</Citation><ArticleIdList><ArticleId IdType="pubmed">20089615</ArticleId></ArticleIdList></Reference><Reference><Citation>Vorselaars W, Nell S, Postma EL, Zarnegar R, Drake FT, Duh QY, Talutis SD, McAneny DB, McManus C, Lee JA, Grant SB, Grogan RH, Romero Arenas MA, Perrier ND, Peipert BJ, Mongelli MN, Castelino T, Mitmaker EJ, Parente DN, Pasternak JD, Engelsman AF, Sywak M, D&#x2019;Amato G, Raffaelli M, Schuermans V, Bouvy ND, Eker HH, Bonjer HJ, Vaarzon Morel NM, Nieveen van Dijkum EJM, Vrielink OM, Kruijff S, Spiering W, Borel Rinkes IHM, Valk GD, Vriens MR; International CONNsortium study group. Clinical outcomes after unilateral adrenalectomy for primary aldosteronism. JAMA Surg 2019; 154:e185842. doi:10.1001/jamasurg.2018.5842</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamasurg.2018.5842</ArticleId><ArticleId IdType="pmc">PMC6484800</ArticleId><ArticleId IdType="pubmed">30810749</ArticleId></ArticleIdList></Reference><Reference><Citation>Hannon MJ, Sze WC, Carpenter R, Parvanta L, Matson M, Sahdev A, Druce MR, Berney DM, Waterhouse M, Akker SA, Drake WM. Clinical outcomes following unilateral adrenalectomy in patients with primary aldosteronism. QJM 2017; 110:277&#x2013;281.</Citation><ArticleIdList><ArticleId IdType="pubmed">28180906</ArticleId></ArticleIdList></Reference><Reference><Citation>Sawka AM, Young WF, Thompson GB, Grant CS, Farley DR, Leibson C, van Heerden JA. Primary aldosteronism: factors associated with normalization of blood pressure after surgery. Ann Intern Med 2001; 135:258&#x2013;261.</Citation><ArticleIdList><ArticleId IdType="pubmed">11511140</ArticleId></ArticleIdList></Reference><Reference><Citation>Celen O, O&#x2019;Brien MJ, Melby JC, Beazley RM. Factors influencing outcome of surgery for primary aldosteronism. Arch Surg 1996; 131:646&#x2013;650.</Citation><ArticleIdList><ArticleId IdType="pubmed">8645073</ArticleId></ArticleIdList></Reference><Reference><Citation>Group TS, Wu VC, Chueh SC, Chang HW, Lin LY, Liu KL, Lin YH, Ho YL, Lin WC, Wang SM, Huang KH, Hung KY, Kao TW, Lin SL, Yen RF, Chen YM, Hsieh BS, Wu KD. Association of kidney function with residual hypertension after treatment of aldosterone-producing adenoma. Am J Kidney Dis 2009; 54:665&#x2013;673.</Citation><ArticleIdList><ArticleId IdType="pubmed">19628318</ArticleId></ArticleIdList></Reference><Reference><Citation>Kohler A, Sarkis AL, Heinrich DA, Muller L, Handgriff L, Deniz S, Schneider H, Kunzel H, Ladurner R, Reincke M, Adolf C. Renin, a marker for left ventricular hypertrophy, in primary aldosteronism: a cohort study. Eur J Endocrinol 2021; 185:663&#x2013;672.</Citation><ArticleIdList><ArticleId IdType="pubmed">34468397</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen YY, Lin YH, Huang WC, Chueh E, Chen L, Yang SY, Lin PC, Lin LY, Lin YH, Wu VC, Chu TS, Wu KD. Adrenalectomy improves the long-term risk of end-stage renal disease and mortality of primary aldosteronism. J Endocr Soc 2019; 3:1110&#x2013;1126.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6507624</ArticleId><ArticleId IdType="pubmed">31086833</ArticleId></ArticleIdList></Reference><Reference><Citation>Kobayashi H, Abe M, Nakamura Y, Takahashi K, Fujita M, Takeda Y, Yoneda T, Kurihara I, Itoh H, Tsuiki M, Wada N, Ichijo T, Katabami T, Ogawa Y, Kawashima J, Yoshimoto T, Sone M, Inagaki N, Watanabe M, Kamemura K, Matsuda Y, Izawa S, Tanabe M, Tanabe A, Suzuki T, Naruse M; JPAS/JRAS Study Group. Association between acute fall in estimated glomerular filtration rate after treatment for primary aldosteronism and long-term decline in renal function. Hypertension 2019; 74:630&#x2013;638.</Citation><ArticleIdList><ArticleId IdType="pubmed">31327258</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu VC, Chueh SJ, Chen L, Chang CH, Hu YH, Lin YH, Wu KD, Yang WS; TAIPAI Study Group. Risk of new-onset diabetes mellitus in primary aldosteronism: a population study over 5 years. J Hypertens 2017; 35:1698&#x2013;1708.</Citation><ArticleIdList><ArticleId IdType="pubmed">28661412</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmed AH, Gordon RD, Sukor N, Pimenta E, Stowasser M. Quality of life in patients with bilateral primary aldosteronism before and during treatment with spironolactone and/or amiloride, including a comparison with our previously published results in those with unilateral disease treated surgically. J Clin Endocrinol Metab 2011; 96:2904&#x2013;2911.</Citation><ArticleIdList><ArticleId IdType="pubmed">21778218</ArticleId></ArticleIdList></Reference><Reference><Citation>Velema M, Dekkers T, Hermus A, Timmers H, Lenders J, Groenewoud H, Schultze Kool L, Langenhuijsen J, Prejbisz A, van der Wilt GJ, Deinum J; SPARTACUS Investigators. Quality of life in primary aldosteronism: a comparative effectiveness study of adrenalectomy and medical treatment. J Clin Endocrinol Metab 2018; 103:16&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pubmed">29099925</ArticleId></ArticleIdList></Reference><Reference><Citation>Citton M, Viel G, Torresan F, Rossi GP, Iacobone M. Effect of unilateral adrenalectomy on the quality of life of patients with lateralized primary aldosteronism. BMC Surg. 2019; 18:105.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7402567</ArticleId><ArticleId IdType="pubmed">31074381</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu VC, Wang SM, Huang KH, Tsai YC, Chan CK, Yang SY, Lin LY, Chang CC, Lu CC, Lin YH, Chen YM, Chueh JS. Long-term mortality and cardiovascular events in patients with unilateral primary aldosteronism after targeted treatments. Eur J Endocrinol 2021; 186:195&#x2013;205.</Citation><ArticleIdList><ArticleId IdType="pubmed">34851859</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu SY, Chu CC, Tsui TK, Wong SK, Kong AP, Chiu PW, Chow FC, Ng EK. Aldosterone-producing adenoma in primary aldosteronism: CT-guided radiofrequency ablation-long-term results and recurrence rate. Radiology 2016; 281:625&#x2013;634.</Citation><ArticleIdList><ArticleId IdType="pubmed">27232638</ArticleId></ArticleIdList></Reference><Reference><Citation>Bouhanick B, Delchier MC, Lagarde S, Boulestreau R, Conil C, Gosse P, Rousseau H, Lepage B, Olivier P, Papadopoulos P, Trillaud H, Cremer A, group A. Radiofrequency ablation for adenoma in patients with primary aldosteronism and hypertension: ADERADHTA, a pilot study. J Hypertens 2021; 39:759&#x2013;765.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7969174</ArticleId><ArticleId IdType="pubmed">33196558</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao Z, Liu X, Zhang H, Li Q, He H, Yan Z, Sun F, Li Y, Zhou X, Bu X, Wu H, Shen R, Zheng H, Yang G, Zhu Z; Chongqing Endocrine Hypertension Collaborative Team. Catheter-based adrenal ablation remits primary aldosteronism: a randomized medication-controlled trial. Circulation 2021; 144:580&#x2013;582.</Citation><ArticleIdList><ArticleId IdType="pubmed">34398686</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang H, Li Q, Liu X, Zhao Z, He H, Sun F, Hong Y, Zhou X, Li Y, Shen R, Bu X, Yan Z, Zheng H, Yang G, Zhu Z; Chongqing Endocrine Hypertension Collaborative Team. Adrenal artery ablation for primary aldosteronism without apparent aldosteronoma: an efficacy and safety, proof-of-principle trial. J Clin Hypertens 2020; 22:1618&#x2013;1626.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8029691</ArticleId><ArticleId IdType="pubmed">32852871</ArticleId></ArticleIdList></Reference><Reference><Citation>Sarwar A, Brook OR, Vaidya A, Sacks AC, Sacks BA, Goldberg SN, Ahmed M, Faintuch S. Clinical outcomes following percutaneous radiofrequency ablation of unilateral aldosterone-producing adenoma: comparison with adrenalectomy. J Vasc Interv Radiol 2016; 27:961&#x2013;967.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5430890</ArticleId><ArticleId IdType="pubmed">27241391</ArticleId></ArticleIdList></Reference><Reference><Citation>Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P, Kolkhof P, Nowack C, Schloemer P, Joseph A, Filippatos G; FIDELIO-DKD Investigators. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med 2020; 383:2219&#x2013;2229.</Citation><ArticleIdList><ArticleId IdType="pubmed">33264825</ArticleId></ArticleIdList></Reference><Reference><Citation>Pitt B, Filippatos G, Agarwal R, Anker SD, Bakris GL, Rossing P, Joseph A, Kolkhof P, Nowack C, Schloemer P, Ruilope LM; FIGARO-DKD Investigators. Cardiovascular events with finerenone in kidney disease and type 2 diabetes. N Engl J Med 2021; 385:2252&#x2013;2263.</Citation><ArticleIdList><ArticleId IdType="pubmed">34449181</ArticleId></ArticleIdList></Reference><Reference><Citation>Bakris G, Pergola PE, Delgado B, Genov D, Doliashvili T, Vo N, Yang YF, McCabe J, Benn V, Pitt B; BLOCK-CKD Study Group. Effect of KBP-5074 on blood pressure in advanced chronic kidney disease: results of the BLOCK-CKD study. Hypertension 2021; 78:74&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8189259</ArticleId><ArticleId IdType="pubmed">33966452</ArticleId></ArticleIdList></Reference><Reference><Citation>Mulatero P, Monticone S, Burrello J, Veglio F, Williams TA, Funder J. Guidelines for primary aldosteronism: uptake by primary care physicians in Europe. J Hypertens 2016; 34:2253&#x2013;2257.</Citation><ArticleIdList><ArticleId IdType="pubmed">27607462</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams B, MacDonald TM, Morant SV, Webb DJ, Sever P, McInnes GT, Ford I, Cruickshank JK, Caulfield MJ, Padmanabhan S, Mackenzie IS, Salsbury J, Brown MJ; British Hypertension Society Programme of Prevention and Treatment of Hypertension With Algorithm Based Therapy (PATHWAY) Study Group. Endocrine and haemodynamic changes in resistant hypertension, and blood pressure responses to spironolactone or amiloride: the PATHWAY-2 mechanisms substudies. Lancet Diabetes Endocrinol 2018; 6:464&#x2013;475.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5966620</ArticleId><ArticleId IdType="pubmed">29655877</ArticleId></ArticleIdList></Reference><Reference><Citation>Agarwal R, Rossignol P, Romero A, Garza D, Mayo MR, Warren S, Ma J, White WB, Williams B. Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial. Lancet 2019; 394:1540&#x2013;1550.</Citation><ArticleIdList><ArticleId IdType="pubmed">31533906</ArticleId></ArticleIdList></Reference><Reference><Citation>Provenzano M, Puchades M, Garofalo C, Jongs N, D&#x2019;Marco L, Andreucci M, De Nicola L, Gorriz J, Heerspink H. Albuminuria-lowering effect of dapagliflozin, eplerenone, and their combination in patients with chronic kidney disease: a randomized cross-over clinical trial. J Am Soc Nephrol 2022. doi:10.1681/ASN.2022020207</Citation><ArticleIdList><ArticleId IdType="doi">10.1681/ASN.2022020207</ArticleId><ArticleId IdType="pmc">PMC9342643</ArticleId><ArticleId IdType="pubmed">35440501</ArticleId></ArticleIdList></Reference><Reference><Citation>Groth H, Vetter W, Stimpel M, Greminger P, Tenschert W, Klaiber E, Vetter H. Adrenalectomy in primary aldosteronism: a long-term follow-up study. Cardiology 1985; 72:107&#x2013;116.</Citation><ArticleIdList><ArticleId IdType="pubmed">3902226</ArticleId></ArticleIdList></Reference><Reference><Citation>Sukor N, Gordon RD, Ku YK, Jones M, Stowasser M. Role of unilateral adrenalectomy in bilateral primary aldosteronism: a 22-year single center experience. J Clin Endocrinol Metab 2009; 94:2437&#x2013;2445.</Citation><ArticleIdList><ArticleId IdType="pubmed">19401369</ArticleId></ArticleIdList></Reference><Reference><Citation>Hundemer GL, Vaidya A. Management of Endocrine Disease: the role of surgical adrenalectomy in primary aldosteronism. Eur J Endocrinol 2020; 183:R183&#x2013;R194.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7853245</ArticleId><ArticleId IdType="pubmed">33077688</ArticleId></ArticleIdList></Reference><Reference><Citation>Burton TJ, Mackenzie IS, Balan K, Koo B, Bird N, Soloviev DV, Azizan EA, Aigbirhio F, Gurnell M, Brown MJ. Evaluation of the sensitivity and specificity of (11)C-metomidate positron emission tomography (PET)-CT for lateralizing aldosterone secretion by Conn&#x2019;s adenomas. J Clin Endocrinol Metab 2012; 97:100&#x2013;109.</Citation><ArticleIdList><ArticleId IdType="pubmed">22112805</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Shea PM, O&#x2019;Donoghue D, Bashari W, Senanayake R, Joyce MB, Powlson AS, Browne D, O&#x2019;Sullivan GJ, Cheow H, Mendichovszky I, Quill D, Lowery A, Lappin D, Gurnell M, Dennedy MC. (11)C-Metomidate PET/CT is a useful adjunct for lateralization of primary aldosteronism in routine clinical practice. Clin Endocrinol 2019; 90:670&#x2013;679.</Citation><ArticleIdList><ArticleId IdType="pubmed">30721535</ArticleId></ArticleIdList></Reference><Reference><Citation>Soinio M, Luukkonen AK, Sepp&#xe4;nen M, Kemppainen J, Sepp&#xe4;nen J, Pienim&#xe4;ki JP, Leijon H, Vesterinen T, Arola J, Lantto E, Helin S, Tikkanen I, Metso S, Mirtti T, Heiskanen I, Norvio L, Tiikkainen M, Tikkanen T, Sane T, V&#xe4;lim&#xe4;ki M, Gomez-Sanchez CE, P&#xf6;rsti I, Nuutila P, Nevalainen PI, Matikainen N. Functional imaging with 11C-metomidate PET for subtype diagnosis in primary aldosteronism. Eur J Endocrinol 2020; 183:539&#x2013;550.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8045447</ArticleId><ArticleId IdType="pubmed">33055298</ArticleId></ArticleIdList></Reference><Reference><Citation>Eisenhofer G, Duran C, Cannistraci CV, Peitzsch M, Williams TA, Riester A, Burrello J, Buffolo F, Prejbisz A, Beuschlein F, Januszewicz A, Mulatero P, Lenders JWM, Reincke M. Use of steroid profiling combined with machine learning for identification and subtype classification in primary aldosteronism. JAMA Netw Open 2020; 3:e2016209.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7525346</ArticleId><ArticleId IdType="pubmed">32990741</ArticleId></ArticleIdList></Reference><Reference><Citation>Turcu AF, Wannachalee T, Tsodikov A, Nanba AT, Ren J, Shields JJ, O&#x2019;Day PJ, Giacherio D, Rainey WE, Auchus RJ. Comprehensive analysis of steroid biomarkers for guiding primary aldosteronism subtyping. Hypertension 2020; 75:183&#x2013;192.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7034384</ArticleId><ArticleId IdType="pubmed">31786984</ArticleId></ArticleIdList></Reference><Reference><Citation>Wannachalee T, Zhao L, Nanba K, Nanba AT, Shields JJ, Rainey WE, Auchus RJ, Turcu AF. Three discrete patterns of primary aldosteronism lateralization in response to cosyntropin during adrenal vein sampling. J Clin Endocrinol Metab 2019; 104:5867&#x2013;5876.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6800532</ArticleId><ArticleId IdType="pubmed">31408156</ArticleId></ArticleIdList></Reference><Reference><Citation>Sam D, Kline GA, So B, Hundemer GL, Pasieka JL, Harvey A, Chin A, Przybojewski SJ, Caughlin CE, Leung AA. External validation of clinical prediction models in unilateral primary aldosteronism. Am J Hypertens 2022; 35:365&#x2013;373.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8976177</ArticleId><ArticleId IdType="pubmed">34958097</ArticleId></ArticleIdList></Reference><Reference><Citation>Kobayashi H, Abe M, Soma M, Takeda Y, Kurihara I, Itoh H, Umakoshi H, Tsuiki M, Katabami T, Ichijo T, Wada N, Yoshimoto T, Ogawa Y, Kawashima J, Sone M, Inagaki N, Takahashi K, Watanabe M, Matsuda Y, Shibata H, Kamemura K, Yanase T, Otsuki M, Fujii Y, Yamamoto K, Ogo A, Nanba K, Tanabe A, Suzuki T, Naruse M. Development and validation of subtype prediction scores for the workup of primary aldosteronism. J Hypertens 2018; 36:2269&#x2013;2276.</Citation><ArticleIdList><ArticleId IdType="pubmed">30020243</ArticleId></ArticleIdList></Reference><Reference><Citation>Burrello J, Burrello A, Pieroni J, Sconfienza E, Forestiero V, Rabbia P, Adolf C, Reincke M, Veglio F, Williams TA, Monticone S, Mulatero P. Development and validation of prediction models for subtype diagnosis of patients with primary aldosteronism. J Clin Endocrinol Metab 2020; 105:e3706&#x2013;e3717. doi:10.1210/clinem/dgaa379</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/clinem/dgaa379</ArticleId><ArticleId IdType="pubmed">32561919</ArticleId></ArticleIdList></Reference><Reference><Citation>Satoh F, Ito S, Itoh H, Rakugi H, Shibata H, Ichihara A, Omura M, Takahashi K, Okuda Y, Iijima S. Efficacy and safety of esaxerenone (CS-3150), a newly available nonsteroidal mineralocorticoid receptor blocker, in hypertensive patients with primary aldosteronism. Hypertens Res 2021; 44:464&#x2013;472.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8019657</ArticleId><ArticleId IdType="pubmed">33199881</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>